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Abstract 
Alzheimer’s disease (AD) is the most prevalent form of dementia affecting the 
elderly population, and its burden is rapidly growing both in Canada and worldwide. As a 
result, there is a substantial need for more effective treatments. The first drug that was 
approved for the management of AD symptoms was tacrine, a dual cholinesterase 
inhibitor. However, tacrine has since been discontinued after signs of hepatotoxicity were 
observed in a considerable proportion of patients. This toxicity has been linked to certain 
metabolites of tacrine formed by oxidation via the hepatic enzyme CYP1A2. Despite this 
issue, tacrine has remained a popular scaffold for the design of novel anti-Alzheimer’s 
agents. While tacrine is an example of the “one drug, one target” approach, a popular 
strategy involves functionalizing tacrine into a multi-targeted compound to target several 
pathways in the complex pathology of AD.  
In this regard, a library of tacrine derivatives was developed that exhibited both 
potent cholinesterase inhibition and the ability to inhibit the formation of the 
characteristic beta-amyloid plaques. Out of 25 starting compounds, nine compounds were 
examined further using in vitro and in silico techniques to investigate binding interactions 
with CYP1A2 and CYP3A4 (to assess potential for hepatotoxicity) and P-gp (to predict 
central nervous system permeability). Three of the remaining nine compounds displayed 
the desired properties and further experiments were conducted with these compounds to 
determine metabolic clearance. These results were incorporated into a physiologically 
based pharmacokinetic model that was used to predict the dose needed to reach target 
brain concentrations in a preclinical study.  
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Chapter 1.0 Introduction 
1.1 History and Impact of Alzheimer’s Disease 
 Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, and is 
currently the most common cause of cognitive dysfunction in the elderly population. It 
was identified in 1906 by Alois Alzheimer, who first described the symptoms and 
neuropathological traits of the disease that would later bear his name.1 In the United 
States, 5.3 million people suffer from AD and the costs associated with AD and related 
dementias will total $226 billion in 20152; a Canadian study conducted in 2011 estimated 
that 747,000 Canadians live with cognitive impairment, with associated costs of $33 
billion per year.3 These figures are quickly increasing, as the fastest growing age 
demographic in Canada and the United States continues to be those 85 years and older. 
Considering that the risk of developing AD doubles every five years after age 65, the 
prevalence and economic liability of AD are predicted to quadruple by 2050. 4  
 
1.2 The Cholinergic Hypothesis 
 Despite the tremendous social and economic burdens of this disease, the 
compounds available for the treatment of AD only offer symptomatic relief and are 
unable to alter the course of the disease.  A major obstacle in the development of 
effective AD treatments is its complex pathogenesis. No single cause has been identified; 
rather, a number of inter-related hypotheses have been proposed. The idea that has 
inspired almost all existing anti-Alzheimer’s agents is the cholinergic hypothesis, which 
suggests that the symptoms of AD can be attributed to decreased activity of the enzyme 
choline acetyltransferase (ChAT) in the cortex and hippocampus. ChAT synthesizes the 
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neurotransmitter acetylcholine (ACh) from the compounds acetyl-CoA and choline 
(Figure 1), and a correlation between loss of ChAT activity and formation of 
neurofibrillary tangles and senile plaques (two anatomical hallmarks of AD) was first 
noted in the 1970s.5 Anatomical studies have indicated that the cortex is not uniformly 
affected, and suggest that the disease begins in the hippocampus, followed by the 
temporal, frontal and parietal lobes.6 This proposed pathology aligns well with clinical 
observations, as the earliest and most prominent symptom of AD is loss of memory, a 
function in which the hippocampus has a substantial role.7 The idea that the pathogenesis 
of Alzheimer’s disease was related to the degradation of a specific cell population led to 
the hope that cholinergic replacement would be as successful as dopamine replacement in 
the treatment of Parkinson’s disease. Several metabolic precursors8,9 and cholinergic 
agonists10 reached clinical trials, but were unsuccessful in improving disease state.11 
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Figure 1. Synthesis and degradation of acetylcholine. (1) ACh is synthesized from the 
precursors acetyl-CoA and choline by ChAT. (2) ACh is stored in vesicles, which then 
undergo fission (3) to release ACh so that it may bind to receptors. (4) After dissociating 
from the receptor, ACh is hydrolyzed by AChE into acetate and choline, which is 
recycled into the pre-synaptic neuron to produce more ACh. 
 
1.2.1 Cholinesterase Inhibitors 
 As a result, new strategies were developed to increase ACh levels in the brain. 
ACh is regularly hydrolyzed by acid catalysis through the cholinesterase enzymes, 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). 12  Under normal 
physiological conditions, AChE is primarily responsible for the degradation of ACh, but 
BuChE levels rise in late-stage AD patients such that BuChE becomes the primary 
catalyst for ACh hydrolysis.13 It was hypothesized that the inhibition of these enzymes 
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could maintain ACh levels. Today, cholinesterase inhibitors (ChEIs) represent the major 
class of compounds used in the pharmacotherapy of AD; among the four drugs approved 
in Canada for the management of AD symptoms, three are ChEIs (Figure 2).14 These 
agents include donepezil (Aricept®), galantamine (Reminyl®) and rivastigmine 
(Exelon®); the fourth option, memantine (Namenda®), is an N-methyl-D-aspartate 
receptor antagonist and can be used alone or in combination with donepezil in severe 
cases of AD.15 However, these compounds only treat the symptoms of mild to moderate 
AD rather than stopping or reversing the disease progression, indicating a need to target 
multiple pathways to find more effective therapies. 
 
Figure 2. Chemical structure of existing cholinesterase inhibitors used in the treatment of 
Alzheimer’s disease. 
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1.3 The Amyloid Cascade Hypothesis 
 
 In the early 1990s, a new hypothesis emerged that suggested that the amyloid-β 
protein (Aβ) that forms the characteristic plaques observed in AD brain is actually a 
principal driver of AD pathology rather than a marker of the disease.16 Aβ peptide is 
produced by the proteolysis of the much larger, membrane-associated amyloid precursor 
protein (APP). The processing of APP can follow one of two pathways: amyloidogenic or 
non-amyloidogenic. In the non-amyloidogenic pathway, APP is cleaved within the Aβ 
domain of the protein by α-secretase, preventing the formation of Aβ protein. 
Alternatively, APP may be cleaved by β-secretase near the N-terminus of the Aβ region 
and by γ-secretase near the C-terminus, thus releasing Aβ protein (Figure 3). The C-
termini of these proteins contain several hydrophobic residues that allow the peptide to 
aggregate into dimers, oligomers and fibrils.17  Although it has been shown to consist of 
anywhere between 39 and 43 amino acid residues, the two primary forms are the species 
comprised of 40 and 42 amino acid (Aβ40 and Aβ42, respectively). Although Aβ42 only 
accounts for ~10% of total secreted Aβ, it is the most toxic form of amyloid aggregates.18 
These amyloid species modify the electrical activity of surrounding neurons, thus causing 
neuronal dysfunction.19 
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Figure 3. Release of Aβ protein following cleavage by β- and γ-secretase, and 
subsequent aggregation into dimers, oligomers and fibrils. 
 
1.3.1 AChE-Induced Amyloid Aggregation 
Shortly after its introduction, a concrete link between the amyloid cascade and 
cholinergic hypotheses was identified. AChE, the enzyme primarily responsible for ACh 
degradation, was found to co-localize with Aβ deposits, forming a neurotoxic complex at 
the peripheral anionic site (PAS) of the enzyme.20 The PAS is composed of five residues 
(Tyr70, Asp72, Tyr121, Trp279 and Tyr334) and serves to guide ACh into the catalytic 
site, which is found at the bottom of a 20 Å gorge.21 In AChE-promoted amyloid 
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aggregation, it is proposed that the PAS acts as a nucleation centre to accelerate the 
assembly of Aβ fibrils, which is consistent with the observation of AChE within the 
senile plaques in AD brains. Furthermore, Aβ-AChE complexes have been shown to be 
more toxic than Aβ fibrils alone. An in vivo study in rat hippocampus showed larger 
amyloid deposits, extensive astrocytosis and greater neuronal cell death in animals 
injected with Aβ-AChE complexes compared to Aβ injections alone.22  
 
1.4 Tacrine 
 Tacrine (Cognex®) was the first compound to be approved by the US Food and 
Drug Administration (FDA) for the management of AD symptoms. It is a potent inhibitor 
of both AChE and BuChE, binding primarily in the catalytic site.23 However, tacrine has 
since been removed from the market due to adverse effects, including hepatotoxicity in a 
significant percentage of patients. 24  This toxicity has been attributed to certain 
metabolites produced when tacrine undergoes oxidative hydroxylation by the hepatic 
enzyme cytochrome P450 1A2 (CYP1A2). This addition can occur at the C-1, C-2, C-4 
and C-7 positions, and subsequent rearrangement to a reactive 7-quinone methide 
intermediate can occur (Figure 4). This species is able to bind irreversibly to surrounding 
macromolecules, causing hepatocellular necrosis.25 This mechanism is similar to that of 
acetaminophen, which also produces a quinone-based metabolite causing liver toxicity.26 
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Figure 4. Metabolic profile of tacrine illustrating the formation of a reactive quinone 
methide species (red box) via metabolism of CYP1A2 
 
1.4.1 CYP1A2 
 The cytochrome P450 family of enzymes catalyze the oxidative metabolism of a 
wide variety of xenobiotics, including approximately 75% of total drug metabolism.27  
Although CYP3A4 catalyzes the majority of these reactions, a growing focus has been 
placed on the CYP1A2 isozyme due to its potentially clinically relevant role in an 
increasing number of compounds.28 Most CYP1A2 substrates, including tacrine, can be 
categorized as polycyclic aromatic hydrocarbons; high lipophilicity, neutral or basic 
behaviour, low molecular volume (< 200 Å3) and the presence of at least one hydrogen 
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bond donor are also common traits among CYP1A2 substrates.29 The small size and 
planar nature of most CYP1A2 substrates is due to its relatively narrow active site (375 
Å3) compared to other CYPs (e.g. 1385 Å3 for CYP3A4).30 The substrate-binding site is 
enclosed by the Phe226 residue on Helix F and the Gly316-Ala317 peptide on Helix I, 
which form two parallel platforms on either side of the binding cavity. Each of these 
helices also contains a polar residue (Thr223 on Helix F; Asp320 on Helix I) that 
undergoes strong hydrogen bonding interactions to stabilize the shape of the active site. 
Several polar amino acids can also be found near the entrance to the CYP1A2 active site 
(Thr118, Ser122 and Thr124) that are unique to this CYP450 isozyme and are thought to 
contribute to substrate positioning through hydrogen bonds (Figure 5).31 Furthermore, 
studies using the random mutagenesis approach have shown that CYP1A2 catalytic 
activity is substantially reduced when mutations occur at the Phe226 and Asp320 
residues, providing further evidence of the major roles these amino acids play in substrate 
binding.32 
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Figure 5. Left: 3D structure of CYP1A2 (PDB file name: 2HI4). Right: The CYP1A2 
active site. Dark red: heme prosthetic group; green: key amino acids.  
 
1.4.2 Tacrine-Based Derivatives as Potential Anti-Alzheimer’s Agents 
 Despite this issue of toxicity, tacrine remains a popular framework for the design 
of novel anti-Alzheimer’s agents with the ability to target multiple factors associated in 
AD pathophysiology. Typically, an analogue will feature a new functional group at the C-
9 amine of tacrine to combine its inhibitory activity toward cholinesterases with another 
therapeutic action. These added functional groups may contribute to antioxidant 
activity, 33  vascular relaxation, 34  anti-amyloid aggregation, 35  or NMDA reception 
modulation. 36  In addition to targeting multiple pathways in AD pathology, these 
derivatives are designed with the intent of reducing the adverse effects observed with 
tacrine, with particular emphasis on hepatotoxicity.  In this regard, Wesseem Osman, a 
former graduate student in Dr. Nekkar Rao’s lab at the University of Waterloo, developed 
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a library of novel tacrine derivatives (Figure 6).37 These compounds incorporate moieties 
from curcumin and resveratrol, which are known antioxidants and are involved in the 
degradation of Aβ oligomers.38,39 The novel tacrine derivatives prepared by Osman act as 
dual inhibitors of both cholinesterase enzymes with anti-amyloid aggregation properties. 
They exhibit potent cholinesterase inhibition, with half maximal inhibitory concentration 
(IC50) in the nanomolar to micromolar range. Additionally, selected compounds have 
been shown in vitro to inhibit self-induced amyloid aggregation of Aβ40 (65.8-97.1% at 
25 µM) and Aβ42 (49.4-81.4% at 25 µM) in in vitro experiments, which is significantly 
greater than the inhibition observed for tacrine (7% at 100 µM), donepezil (22% at 100 
µM),40 and galantamine (~40% at 50 µM).41 These compounds are also predicted to 
inhibit AChE-induced amyloid aggregation through interaction at the peripheral anionic 
site of AChE, based on in silico molecular docking experiments. Although these 
derivatives displayed potent activity towards multiple AD pathways, it was still unknown 
whether these derivatives would also form hepatotoxic metabolites in vivo due to their 
structural similarity to tacrine. We addressed this by investigating the binding affinity and 
orientation of these novel tacrine derivatives within CYP1A2 in silico and by performing 
in vitro metabolism experiments to identify metabolites and evaluate clearance. 
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Figure 6. Chemical structures of novel tacrine derivatives. Compounds are named by 
combining the letter for their class and the number for the appropriate substituent. For 
example, B2 is 6-chloro-N-(2-methoxybenzyl)-tacrine. 
 
1.5 Development of CNS-Targeted Drugs 
 
 Despite a relatively high prevalence, neurological and psychiatric disorders apply 
a disproportionately large burden on global health systems. One way of quantifying the 
burden of a chronic disease is in terms of years lived with disability (YLD). In 2000, the 
World Health Organization (WHO) estimated that neuropsychiatric disorders accounted 
for 31% of YLDs worldwide; in developed countries, where infectious diseases and 
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malnutrition are less prevalent, over 40% of YLDs can be attributed to neurodegenerative 
and psychiatric diseases.42 This tremendously high burden emphasizes the urgent need for 
more effective agents against these diseases.  
 However, several large pharmaceutical companies have recently shut down the 
neurological disorders cohorts of their research and development operations. The search 
for new treatments for this group of diseases has become too costly, with the risk of 
failure outweighing the potential rewards. Agents targeting the central nervous system 
(CNS) are much more difficult to develop than other types of drugs, with only 8.2% of 
drug candidates reaching the market compared to 15% of drugs overall. These failings 
also tend to occur in later stages of the drug development process, making their 
development even more resource-intensive. Fewer than half of all CNS candidates that 
reach Phase III trials succeed, compared to a 66% success rate for all other drugs.43 This 
high attrition rate can be due to a number of factors including a lack of predictive animal 
models, an inability to foresee who will benefit from the treatment and the use of 
subjective diagnostic scales to measure outcomes, where fluctuations in a patient’s 
conditions can make it difficult to evaluate cognitive improvement.44 Their long-term use 
also necessitates more testing for safety and efficacy compared to a treatment that lasts 
only a few days. As a result, human testing of CNS agents typically lasts two years longer 
than average drug candidates.  
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1.5.1 Lipophilicity and Other Factors Influencing CNS Permeability 
 Considering the hurdles that must be overcome to develop a new CNS-targeted 
therapy, it is crucial that only the most promising candidates are moved forward and that 
key properties be investigated early in the drug development process. In addition to high 
potency and selectivity for the target, there are a number of other characteristics that 
promote successful CNS activity. The first property to be linked to CNS activity was the 
octanol-water partition coefficient, logP, which is a measure of lipophilicity. Although 
logP has an experimental origin and interpretation, it is now more common to determine 
the calculated logP (ClogP), which can be estimated by a number of different algorithms 
based on the aromatic rings and functional groups contained in the compound. This 
dependence was first reported by Hansch and coworkers in 1967, who found that this 
relationship was parabolic in nature rather than linear.45 Although high lipophilicity does 
facilitate CNS penetration, this parameter can be described as a “double-edged sword.” 
The compound must be lipophilic enough to penetrate the brain, but not so lipophilic that 
its solubility, absorption and metabolic stability are compromised. 46  Increased 
lipophilicity is also associated with a greater likelihood of promiscuous receptor binding, 
resulting in toxicity – a well-documented phenomenon for anaesthetics.47,48 Despite the 
negative influence of high lipophilicity on a compound’s pharmacokinetics (PK) and 
toxicity profile, a current trend in drug discovery is a focus on candidates with high 
molecular weight and high logP values, driven by the enhanced potency of lipophilic 
molecules. This inclination towards achieving potency by increasing size and 
lipophilicity has been termed “molecular obesity,” and has been implicated in high 
attrition rates during drug development.49  
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 A number of other physicochemical properties, some of which are related to 
lipophilicity, have been linked to the success or failure of CNS-targeted drugs. Lipinski, 
known for his Rule of Five describing favourable properties for orally active drugs,50 
developed a more stringent set of criteria for predicting CNS penetration. These include 
lower molecular weight (≤400 g/mol) and fewer hydrogen bond donors and acceptors (≤3 
and ≤7, respectively).51 Sufficient aqueous solubility is crucial, as passive diffusion into 
the brain is driven by the concentration gradient between blood and brain. Molecular 
flexibility, expressed as the number of rotatable bonds in the structure, also plays a role in 
CNS penetration. Increased molecular flexibility impedes the molecule’s ability to 
traverse membranes, so a more rigid structure (fewer than 7 rotatable bonds) is 
desirable.52 
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1.5.2 P-glycoprotein  
 As mentioned, lipophilicity is a key factor in determining the ability of a 
compound to penetrate the CNS but does not guarantee entry into the brain. The blood-
brain barrier (BBB), a highly selective barricade of tightly joined endothelial cells, 
protects the brain from neurotoxins and extracellular fluctuations in hormones or amino 
acids that can lead to uncontrolled brain activity.53 Although highly lipophilic compounds 
are able to infiltrate the physical component of the BBB, their entrance into the CNS may 
be modulated by the transporter P-glycoprotein (P-gp). Transport by P-gp poses a 
significant challenge to pharmacologists due to its remarkably extensive poly-specificity, 
binding compounds with a wide range of lipophilicities and molecular weights. 54 
Structurally, P-gp consists of two analogous halves, each containing six transmembrane 
domains (TMDs) and a nucleotide-binding domain (NBD). A funnel-shaped internal 
cavity (6000 Å3) is contained within the TMDs and features a flexible binding pocket 
with hydrophilic groups, charged groups and aromatic amino acids to accommodate a 
wide variety of substrates (Figure 7).55  
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Figure 7. 3D structure of murine P-gp (PDB file name: 3G61) in the inward-facing 
conformation.  
 
At the start of the catalytic cycle, P-gp is in its inward-facing conformation and 
the compound binds to one of the high affinity sites found within the TMDs, entering 
from either the inner leaflet of the membrane or from the cytoplasmic side of the protein. 
The binding of the drug increases the affinity of P-gp for ATP and induces a 
conformational change in which the NBDs dimerize while each is bound to a molecule of 
ATP; this is called the outward-facing conformation. This change in conformation 
reduces the activation energy and moves the drug to a lower affinity site, from which it is 
released following the hydrolysis of ATP. The second molecule of ATP is hydrolyzed 
and the energy provided is used to separate the NBD dimer, resetting the protein to its 
initial state (Figure 8).56,57 An alternate model for this transport cycle has been suggested, 
which also requires the hydrolysis of two molecules of ATP. However, this model 
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proposes that only one molecule of ATP is bound at any given time, with the first ATP 
hydrolysis powering the efflux of the drug and the second serving to return P-gp to its 
ground state  
 
Figure 8. The P-gp catalytic cycle: Drug binds to a high affinity site (hexagon) within the 
TMDs. One molecule of ATP binds to each of the NBDs, causing them to dimerize and 
moving the drug to a low affinity site (oval). Hydrolysis of one molecule ATP to ADP 
and Pi powers the release of the drug. The second molecule of ATP is hydrolyzed to 
separate the NBD dimer, resetting P-gp to its initial, inward-facing conformation. 
 
A drug’s relationship with P-gp, whether it is a substrate, inhibitor or inducer, can 
have many clinically significant implications. If a CNS-targeted drug undergoes transport 
by P-gp, it can be difficult to reach the concentration needed to observe a therapeutic 
effect. For other orally administered drugs, P-gp can also present a challenge. P-gp is 
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expressed in the apical intestinal membrane, where liver enzymes including CYP3A4 are 
also found. There is known to be considerable overlap in the substrate specificities of P-
gp and CYP3A4, so repeated transport by P-gp across the intestinal membrane provides 
greater opportunity for intestinal metabolism to occur, resulting in low oral 
bioavailability.58 As a result, oral absorption and CNS penetration can be improved by 
concomitant use of P-gp inhibitors, which has been demonstrated with the anticancer 
drug paclitaxel.59 However, the simultaneous use of P-gp substrates and inhibitors can 
also result in adverse effects. For example, colchicine is a CYP3A4 and P-gp substrate 
that, when taken with an inhibitor of these enzymes, can be lethal; more than 60 deaths 
have been linked to the co-administration of colchicine and the antibiotic clarithromycin, 
a strong inhibitor of CYP3A4 and P-gp.60 For these reasons, it is very important to 
determine how a drug candidate interacts with P-gp. 
 
1.6 Physiologically Based Pharmacokinetic Modelling in Drug Development 
 Physiologically based pharmacokinetic (PBPK) modelling is an in silico 
technique that can be employed in numerous stages of drug discovery and development, 
including first-in-human trials, drug-drug interaction studies and candidate selection.61 
These models incorporate both the properties of the compound of interest (such as 
molecular weight, ClogP, acid-base behaviour, fraction unbound and tissue-plasma 
partition coefficients) and the anatomical and physiological characteristics of the 
organism (such as blood flows, organ volumes, and tissue compositions). Each 
compartment within the model represents a specific organ, and the compartments are 
interconnected via the circulatory system. The drug transfer across all compartments is 
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expressed as a series of mass balance differential equations, and the amount of drug in 
any compartment can be calculated for any given time.62 Because they are mechanistic in 
nature, these models can be used to extrapolate between species, maturational stages and 
disease states, offering a distinct advantage over empirically derived pharmacokinetic 
models where the compartments have little biological relevance. Their mechanistic nature 
also permits explicit definition of important processes that affect compound disposition 
such as transporter and metabolic activity. 
 The ability to predict CNS permeability and brain concentrations is one of the 
major difficulties in developing CNS-targeted drugs, and is an area where PBPK models 
can be useful. A number of PBPK models of the CNS have been reported,63-6563,64,65 with 
varying degrees of detail, but an emphasis has recently been placed on the use of an in 
vitro-in vivo extrapolation (IVIVE) strategy. This approach uses scaling factors to 
transform in vitro data, such as clearance, transport activity and permeability, to account 
for differences between the in vitro and in vivo environments.66 Through integration of 
this data within a PBPK model framework, disposition of the compound in any organ 
(e.g. brain) can be predicted in a biologically rational manner. 
  
	   21 
Chapter 2.0 Objectives and Hypotheses 
 
Overall Objective: To identify the most promising candidates from a library of tacrine 
derivatives for further development by investigating their risk for hepatotoxicity, CNS 
permeability and metabolic stability 
  
Objective 1: To evaluate tacrine and its derivatives (Figure 6) as potential substrates of 
CYP1A2 
• Aim 1: Conduct in vitro CYP1A2 assays and calculate IC50 values 
o Hypothesis: Chemical modification of tacrine will alter its binding to 
CYP1A2. As a result, these derivatives will have different substrate 
profiles as compared to tacrine. 
• Aim 2: Conduct in silico molecular modelling experiments to determine binding 
modes and energy of the ligand-enzyme complexes 
o Hypothesis: The larger molecular volumes of the tacrine derivatives will 
limit their ability to fit within the narrow CYP1A2 binding site. 
• Aim 3: Correlate the results of the in vitro and in silico experiments to determine 
the utility of in silico models for predicting substrate behaviour 
o Hypothesis: A correlation between IC50 and energy parameters for the 
complex will emerge, linking structural modifications and CYP1A2 
substrate behaviour 
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Objective 2: To evaluate tacrine and its derivatives as potential substrates towards P-gp 
• Aim 1: Establish clinically relevant P-gp activity by measuring in vitro IC50 
values and comparing donepezil, a current AD therapy whose behaviour towards 
P-gp is not well-defined, with ketoconazole, a known P-gp inhibitor 
o Hypothesis: By comparing the binding interactions and ligand-enzyme 
complex energy of donepezil within P-gp to those of ketoconazole, the 
role of P-gp in donepezil’s disposition can be clarified and serve as a 
reference for clinically relevant P-gp activity.  
• Aim 2: Complete analogous in silico and in vitro experiments with tacrine, and 
derivatives and compare with reference compounds ketoconazole and donepezil 
o Hypothesis: It has been reported that the tacrine is not a substrate for P-gp. 
However, it is possible that the addition of large substituents at the C-9 
position will result in enhanced P-gp binding. 
• Aim 3: Correlate the results of the in vitro and in silico experiments to determine 
the utility of in silico models for prediction of substrate behaviour 
o  Hypothesis: The combination of in vitro and in silico data will allow us to 
more confidently predict P-gp substrate behaviour. 
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Objective 3: To assess the metabolic profile of the tacrine derivatives 
• Aim 1: Isolate rat liver microsomes and quantify their protein content and 
CYP450 reductase activity 
• Aim 2: Calculate in vitro intrinsic clearance using a substrate depletion approach 
o Hypothesis: It is expected that the tacrine derivatives will be more 
metabolically stable (i.e. will have a lower intrinsic clearance) than 
tacrine. 
 
Objective 4: To develop PBPK models for tacrine and its derivatives 
• Aim 1: Parameterize a PBPK model for tacrine in rats following intravenous (IV) 
administration and compare to observed data for the purpose of optimizing 
lipophilicity, intrinsic clearance and transport activity  
• Aim 2: Determine scaling factors to convert in vitro metabolism and distribution 
parameters from those parameters optimized in the tacrine model  
• Aim 3: Develop PBPK models for tacrine derivatives using the same scaling 
factors and derivative-specific in vitro data  
• Aim 4: Use the models to predict the IV dose required to reach appropriate brain 
concentrations 
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Chapter 3.0 Methods 
 
3.1 Initial Compound Selection 
 As mentioned, there are a number of physicochemical properties that are useful in 
predicting the success or failure of a CNS-targeted drug. First and foremost, the 
compound must be able to achieve therapeutic levels in the target organ. For the tacrine 
derivatives, target affinity was measured as the half maximal inhibitory concentration 
(IC50) towards AChE or BuChE. Since AChE is the primary catalyst for acetylcholine 
hydrolysis, potency towards this enzyme exhibited by tacrine derivatives was analyzed. 
Among the cholinesterase inhibitors currently available, rivastigmine (Exelon®) has the 
highest AChE inhibitory potency (IC50 = 4.15 ± 0.16 µM67) and so only tacrine 
derivatives that exhibited better potency than rivastigmine were moved forward.  
 Lipophilicity has also been highlighted as a key predictor of a compound’s PK 
profile. Highly lipophilic compounds tend to have poor solubility, low absorption, 
metabolic instability and greater risk of toxicity, while hydrophilic molecules are more 
likely to have difficulties permeating the blood-brain barrier. Noting that the ClogP 
values for the tacrine library used in this project ranges from 4.02 to 6.64, a lower 
boundary was not required. In Lipinski’s modified Rule of Five for CNS-target 
compounds, a logP < 5 is desirable. Based on AChE inhibition profile, we considered an 
upper limit of 6 for ClogP values for tacrine derivatives. High potential for hydrogen 
bonding (i.e. >7 nitrogen or oxygen atoms or >3 NH or OH groups) did not result in the 
exclusion of any compounds. 
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3.2 Molecular Modelling Studies 
 
This project made use of the Discovery Studio 4.0 Structure-Based Design 
software from BIOVIA/Accelrys Inc. (San Diego, USA) to investigate compound-
enzyme interactions with both CYP450 enzymes and the transporter P-gp. The tacrine 
derivatives were constructed using the Build Fragment module and their geometries were 
optimized by 500 steps of steepest descent, followed by conjugate gradient minimization 
(0.1 kcal/mol). These experiments utilized the Chemistry at Harvard Macromolecular 
Mechanics (CHARMm) force field and the implicit solvent function Generalized Born 
with a simple Switching (GBSW). The crystal structures of CYP1A2, CYP3A4 and P-gp 
were obtained from the protein data bank (2HI4.pdb, 2V0M.pdb and 3G61.pdb, 
respectively). In each case, the structure contains the enzyme bound to a known substrate 
or inhibitor; α-naphthoflavone for CYP1A2, ketoconazole for CYP3A4 and the ligand 
QZ59 for P-gp. These molecules are used to define a binding site by creating a sphere 
around each ligand with a radius of 10 Å for the CYP450 enzymes and 20 Å for P-gp. 
After defining the binding site, the ligands are removed along with all water molecules. 
 Ligand-enzyme docking was completed using a simulated annealing protocol 
consisting of 2000 heating steps with a target temperature of 700 K and 5000 cooling 
steps with a target temperature of 300 K to generate the 10 most favourable docked 
ligand poses (CDOCKER algorithm). These poses were ranked using the CDOCKER 
energy and CDOCKER interaction energy parameters (both in kcal/mol). The lowest 
energy ligand-enzyme complex for each compound was further evaluated by 
investigating key polar and nonpolar interactions including hydrogen bonding, 
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electrostatic interactions and van der Waals interactions. This protocol was validated by 
investigating the binding mode of the known CYP1A2 inhibitor α-naphthoflavone within 
the CYP1A2 active site and comparing the results with its known crystal structure.31 
Similar protocols were used to investigate the binding interactions of tacrine derivatives 
with CYP3A4 and P-gp. 
 
3.3 Recombinant CYP450 Assays 
The human CYP450 assay kits were obtained from Life Technologies, Burlington, 
Canada (catalogue numbers P2863 and P2857 for CYP1A2 and CYP3A4, respectively). 
The assay principle is based on the conversion of a lactone-based substrate into highly 
fluorescent chromophores by human CYP450 enzyme, which is measured as relative 
fluorescence units (RFUs). This metabolism converts the substrate from its non-
fluorescent blocked form to an extremely fluorescent free form (Figure 9). The reaction 
was initiated by the conversion of NADP+ to NADPH, which is a necessary co-factor of 
the fluorescence-generating reaction. Test compounds are evaluated based on their ability 
to inhibit this fluorescent signal. 
Stock solutions of test compounds were prepared in organic solvent dimethyl 
sulfoxide (DMSO) for CYP1A2 and methanol (MeOH) for CYP3A4, then diluted with 
phosphate buffer (pH 8.0) to obtain desired concentrations (final test compound 
concentrations: 0.01, 0.1, 1, 10 and 20 µM; maximum DMSO/MeOH concentration used 
was 4% v/v). This assay utilizes a solution of microsomes prepared from insect cells that 
express a single P450 isozyme, CYP1A2 or CYP3A4, and human CYP450 reductase in 
100mM potassium phosphate buffer (pH 8.0). Additionally, a regeneration system 
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consisting of glucose-6-phosphate and glucose-6-phosphate dehydrogenase is required for 
the conversion of NADP+ to NADPH to initiate the reaction.  
Readings were obtained in a black, clear-bottom 96-well plate using a Molecular 
Devices SpectraMax M5 plate reader in fluorescence mode. For CYP1A2, the excitation 
and emission wavelengths were 415 nm and 460 nm, respectively; for CYP3A4, the 
excitation and emission wavelengths were 490 nm and 520 nm, respectively. Each well 
contains 40 µL of test compound (concentration range used: 0.01-20 µM) and 50 µL of a 
Master Pre-Mix containing the recombinant enzyme and regeneration system described 
above. During incubation, a solution of NADP+ and the Vivid® EOMCC (CYP1A2) or 
DBOMF (CYP3A4) substrate was prepared in supplied reaction buffer. The reaction was 
initiated by adding 10 µL of the NADP+/substrate mixture to each well and the 
fluorescence was measured every minute for 15 minutes (Figure 9). A final reading is 
taken five minutes after the addition of 50 µL of stop reagent (0.5 M 
tris(hydroxymethyl)aminomethane (tris) base). The assay protocol was validated by 
preparing a standard curve using a supplied fluorescent standard at various concentrations 
(0, 7.8, 15.6, 31.2, 62.5, 125, 250, 500 nM; R2 = 0.9997) 
Each 96-well plate contains reference agents and controls. For both assays, tacrine 
was included for comparison. For the CYP1A2 assay, the strong inhibitor α-
naphthoflavone was included as a positive control; cimetidine, a weak inhibitor of 
CYP1A2, was also included as a negative control to compare and validate the results 
obtained. In the case of CYP3A4, ketoconazole (a strong inhibitor of CYP3A4) served as 
positive control. Negative controls containing no inhibitor were also included to record 
100% CYP450 activity. The degree of inhibition for each compound was calculated as a 
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half maximal inhibitory concentration (IC50). The experiments were run in triplicate (n = 
3) and were reported as the average IC50 ± SD of two independent experiments. 
 
Figure 9. (A) Substrate cleavage by CYP450 produces the highly fluorescent form of the 
compound, which is detected. (B) A typical 96-well plate for CYP450 assay. The blue, 
teal, purple and pink wells represent four test compounds at five different concentrations 
in triplicate, one of which is a control (e.g. α-naphthoflavone). The orange wells represent 
the negative controls, which contain no test compound. The grey wells contain the 
highest test compound concentration used in the assay, to confirm there is no interference 
from the compounds. Similarly, the green wells verify that solvent does not interfere with 
the fluorescent signal. (C) Addition sequence for CYP450 assay.  
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3.4 P-glycoprotein Assay  
 
The P-gp (MDR1 or ABCB1) activity was evaluated by detecting the effect of 
tacrine and its derivatives on recombinant human P-gp in a cell membrane fraction using 
Pgp-Glo™ assay kit (Promega Corporation, Madison, USA, catalogue number V3601). 
The assay principle is based on the Pgp/ATPase reaction in the presence of substrate 
adenosine triphosphate (ATP) and varying concentrations of test compounds. 
Unmetabolized ATP is detected as a luciferase-generated luminescent signal and 
measured as relative luminescence units (RLUs) as shown in Figure 10. The stock 
solutions of tacrine and derivatives were prepared in methanol and diluted with assay 
buffer to desired concentrations. Each well contains 20 µL of test compound (final 
concentration range 0.01–100 µM per well), sodium vanadate (positive control), 
ketoconazole (P-gp inhibitor), verapamil (P-gp stimulant) or phosphate buffer. After 
adding 20 µL of Pgp membranes, the plates were incubated at 37°C for 5 min. The 
Pgp/ATPase reaction was initiated by adding 10 µL of substrate Mg-ATP. After 40 
minutes of incubation at 37°C, 50 µL of ATP detection reagent was added. The 
luminescent signals were read every two min. for 40 min. in a clear 96-well plate, using a 
BioTek Synergy H1 microplate reader. A standard curve was obtained using various 
concentrations for MgATP (0.37–3.0 mM). The degree of inhibition for each compound 
was expressed as half maximal effective concentrations (EC50 values). The experiments 
were run in triplicates (n = 3) and were reported as average EC50 ± SD of two 
independent experiments. 
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Figure 10. Illustration of ATP-dependent drug transport by P-gp and the subsequent 
reaction of remaining ATP with luciferin to produce luminescence. 
 
It should be noted that there are several in vitro assays that have been used in the 
classification of P-glycoprotein substrates, including monolayer, calcein-AM and the 
ATPase assay described above. The monolayer efflux assay measures bidirectional 
(apical-to-basolateral and basolateral-to-apical) transport across a cell layer. The ratio of 
these two rates of transport is called the efflux ratio, where a value close to 1 indicates an 
absence of transport processes. Although this assay provides the most direct manner of 
measuring efflux, it is also labour-intensive.68 The calcein-AM69 and ATPase70 assays 
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have similar strengths and weaknesses; they are less tedious, but use an indirect method 
to measure P-gp transport. Polli and colleagues71 investigated the concordance between 
these assays and found that all three methods gave the same result for over half of the 
compounds tested. By comparing the compounds’ apparent permeabilities to their results 
for the three assays, they were able to determine regions of poor response for each 
method. For the ATPase assay, this was determined to be compounds with very low 
permeability (<20 nm per second). Since the compounds we are investigating are small 
and lipophilic, it is unlikely that we will be in this region and the ATPase assay will 
correctly identify these compounds are substrates or non-substrates.   
 
3.5 Preparation of Hepatic Microsomes 
 Rat liver samples were collected from three male Sprague-Dawley rats by Dr. 
Binbing Ling (University of Guelph). The rats were anesthetised by inhalation of 
isoflurane. Upon removal, the livers were thoroughly perfused with a buffer containing 
1.15% (w/v) potassium chloride (KCl) and 1 mM ethylene diamine tetraacetic acid 
(EDTA, pH 7.4) until the fluid leaving the tissue was free of blood. This procedure 
serves to enhance the purity of the microsomal preparations. Following perfusion, the 
livers were snap-frozen in liquid nitrogen and stored at -80°C until further processing. 
 The protocol for the preparation of microsomes was adapted from that of Fowler 
and coworkers (Figure 11).72 After thawing on ice, the liver samples were weighed and 
finely minced. Approximately 1 g of liver was transferred to a 7 mL Dounce tissue 
homogenizer (Bellco Glass, Vineland NJ), to which a homogenization buffer (0.05 M 
Tris, 150 mM KCl, 0.1 mM Cleland’s reagent, 1 mM EDTA and 0.25 mM sucrose) was 
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added to obtain a 1:4 w/v tissue/buffer ratio. Also, 100 µL of 50 mM 
phenylmethylsulfonyl fluoride (PMSF) was added. PMSF is a serine protease inhibitor 
and reduces proteolysis of the desired microsomal protein during preparation. The PMSF 
solution was prepared fresh daily as its inhibitory behaviour towards proteases quickly 
decreases if no protease is present (half-life at 25°C, pH 7.0: 110 minutes 73 ). 
Homogenization was achieved through several thrusts with both the large and small 
clearance pestles. The homogenate was transferred to ultracentrifuge tubes and was 
centrifuged at 10,400 rpm (10,000 g) for 20 minutes at 4°C in a Beckman Coulter 70.1 Ti 
fixed angle rotor. The supernatants from these preparations were collected and 
transferred to new ultracentrifuge tubes and centrifuged at 34,000 rpm (100,000 g) for 60 
minutes at 4°C in the same Beckman Coulter rotor as previously. When the run was 
complete, the supernatants were discarded and the pellet was washed in 0.1 M phosphate 
buffer and centrifuged again at 34,000 rpm for 60 minutes at 4°C. After this final spin, 
the supernatants were again discarded and the remaining pellet was reconstituted in a 
storage buffer containing 0.05 M tris and 1 mM EDTA in 20% glycerol such that 1 mL 
of the suspension contained material from 0.5 g of liver. These samples were separated 
into 1.5 mL aliquots and were stored in Eppendorf tubes at -80°C until further use. 
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Figure 11. Experimental flow chart summarizing the isolation of hepatic microsomes 
 
3.5.1 Protein Quantification 
 The method used to quantify the protein present in the microsomal samples was 
first described by Bradford in 1976.74 This assay employs the Coomassie Brilliant Blue 
G-250 dye, which exists in cationic, neutral and anionic forms (Figure 12). These species 
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display maximum absorbance at 470 nm (red), 650 nm (green), and 595 nm (blue), 
respectively. In the acidic environment of the Coomassie dye, the anionic species is not 
present in its free form; as a result, the solution – a mixture of the red cationic and green 
neutral forms – appears brown. However, it is the anionic form that binds to protein; this 
species undergoes significant electrostatic interactions with the positively charged amino 
acid residues arginine, lysine and histidine, as well as van der Waals interactions with 
aromatic residues.75 As the anionic form binds to protein, its free concentration decreases 
and the equilibrium favours further production of the anionic species. As a result, protein 
binding causes an increase in absorption at 595 nm and it is this absorbance that is 
measured to quantify the protein content of a sample.  
 
Figure 12. Chemical structure of the Coomassie dye and the wavelength of maximum 
absorbance for its various species.  
 
 The Coomassie Protein Assay Kit was obtained from Thermo Scientific and 
included 2 mg/mL bovine serum albumin, which was used to prepare a calibration curve 
from 0.1 mg/mL to 1.5 mg/mL. A sample from each rat was serially diluted up to a 160x 
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dilution to ensure overlap with the linear range of the standard. Readings were obtained 
in a clear 96-well plate using a BioTek Synergy H1 microplate reader in absorbance 
mode. Each well contained 5 µL of either albumin standard or microsomes and 250 µL of 
the Coomassie reagent. All samples were present in triplicate, and were allowed to 
incubate for 15 minutes before absorbance at 595 nm was recorded using a Biotek 
Synergy Neo Multi-Mode Reader. A linear least squares fit was used to produce the 
equation for the calibration curve (R2 = 0.9857). Measurements for the microsomal 
samples were compared to the calibration curve and averaged to determine the protein 
content for each rat. 
 
3.5.2 Cytochrome P450 Reductase Activity 
 Cytochrome P450 reductase is a membrane-bound protein found in the 
endoplasmic reticulum and is essential to the metabolic processes catalyzed by the 
cytochrome P450 enzymes. Cytochrome P450 reductase supplies the cytochrome P450s 
with the electrons needed for this catalytic activity, with NADPH serving as the source of 
electrons. A typical P450 reaction can be written as follows: 𝑅𝐻 + 𝑂! + 𝑁𝐴𝐷𝑃𝐻 + 𝐻! → 𝑅𝑂𝐻 + 𝐻!𝑂 + 𝑁𝐴𝐷𝑃! 
where RH is the substrate that is oxidized by the P450, making it more hydrophilic and 
therefore more easily eliminated by the kidneys.76  
 Prior to conducting metabolism studies, it is essential to verify that this electron 
transfer is taking place. To do so, a spectrophotometric titration is performed using a 
surrogate electron acceptor; in this study, potassium ferricyanide is employed, but 1,1-
diphenyl-2-picrylhydrazyl and cytochrome c can also be used for this purpose.77 A 
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Master Mix containing 0.625 mM potassium ferricyanide and a 1 mM stock solution of 
NADPH (final concentrations 0.5 mM and 0.1 mM, respectively) were prepared in 0.3 M 
phosphate buffer (pH 7.4). Protein samples from each rat were standardized to 4 mg/mL, 
then serially diluted in phosphate buffer to produce 2x, 4x, 8x, 16x and 32x dilutions. 
This assay was performed in a clear 96-well plate, with each well containing 10 µL of 
microsomes and 80 µL of the Master Mix. After recording baseline absorbance at 420 
nm for 3 minutes, 10 µL of the NADPH solution was added to each well to initiate the 
reaction. Absorbance at 420 nm was recorded for another 3 minutes. Each diluted sample 
was present in triplicate, and blanks containing no microsomes and no NADPH were also 
included. The rate of ferricyanide reduction (r, in mM min-1) was calculated using the 
following equation, a rearrangement of the Beer-Lambert Law: 
𝑟 = ∆𝐴!"#  𝑚𝑖𝑛!!𝜀   ⋅   ℓ𝓁  
where ΔA420 is the change in absorbance at 420 nm per minute, ε is the extinction 
coefficient for potassium ferricyanide (1.02 mM-1 cm-1) and ℓ𝓁 is the path length (i.e. the 
depth of the reaction mixture within the well, or 0.296 cm). 
 
3.6 Measurement of In Vitro Intrinsic Clearance 
3.6.1 Substrate Depletion Studies 
 Before completing the substrate depletion experiments, incubations at a single 
concentration were conducted to identify metabolites and ensure appropriate reaction 
conditions. In an Eppendorf tube, 500 µM test compound was combined with 2 mg/mL 
microsomal protein and heated to 37°C. To initiate the reaction, NADPH was added to 
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the reaction mixture for a final concentration of 1 mM. After 24 hours, the reaction was 
terminated by addition of 250 µL of ice-cold acetonitrile. After 20 minutes of 
centrifugation at 13,000 g, the supernatant was passed through a 0.45 µm filter and the 
mass of metabolite(s) was determined using an Agilent 1260 infinity series LC-MS (see 
Table 1).  
Table 1. LC-MS conditions for analysis of tacrine and derivatives. 
Column Agilent Poroshell 120 EC-C18                      (4.6 x 50 mm, 2.7 µm) 
Mobile Phase 70% water / 30% acetonitrile with 0.1% TFA 
Injection Volume 10 µL 
Flow rate 0.5 mL/min 
Detector 
Wavelength 254 nm 
 
 Substrate depletion studies were carried out in 96-well plates, with one row 
designated for one of five concentrations (range: 1-500 µM, Figure 13). Each well 
contained 40 µL of test compound, 50 µL of microsomes from Rat #2 and 90 µL of 0.3 
M phosphate buffer. The plate was incubated at 37°C with shaking, and the reaction was 
initiated by addition of 20 µL of NADPH, bringing the total reaction volume to 200 µL. 
Reactions were terminated at specified times (0, 2, 5, 10, 15, 30, 60, 90, 120, 180, 210 
and 240 minutes) by addition of 100 µL of ice-cold acetonitrile. Samples were processed 
as outlined above. The concentration measured by LC-MS for the t = 0 samples is 
considered to be 100% substrate and measurements at later time points are recorded as a 
percentage of this value.  
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Figure 13. Sample 96-well plate setup for substrate depletion studies.  
 
The data for each concentration was fit to the following equation: %𝑆! = 𝑒!!!"#  ×  ! 
where %St is the percentage of substrate remaining at time t and kdep is the depletion rate 
constant. After fitting this equation to each substrate concentration, the data was fit to the 
following equation: 
𝑘!"# = 𝑘!"#([!]→!) 1− [𝑆]𝑆 + 𝐾!  
where kdep([S]è0) is the theoretical rate constant for an imperceptibly low concentration of 
substrate and KM is the Michaelis-Menten constant, which describes the likelihood that a 
compound will saturate a particular metabolic pathway. Finally, kdep([S]è0) was scaled to 
intrinsic clearance using a physiologically based scaling factor. 
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3.6.2 Microsomal Binding Assays 
Microdialysis experiments were conducted to determine the extent of binding to 
microsomal protein in the substrate depletion studies. Before performing microdialysis, a 
calibration curve was prepared for each compound in phosphate buffer (pH 7.4). The 
wavelength of maximum absorbance for each compound was determined by conducting 
a sweep of the UV-visible spectrum and any interference from 100 µM ketoconazole at 
these wavelengths was noted. Protein binding experiments were carried out using the 
QuixSepTM Micro Dialyzer system with a regenerated cellulose membrane (nominal 
molecular weight cut-off: 12,000-14,000 Da; Membrane Filtration Products Inc., Seguin, 
Texas, USA). The protein and test compound are contained in the chamber (total volume: 
500 µL; test compound concentration: 4000 µM; protein concentration: 2 mg/mL), which 
is then placed in a beaker containing phosphate buffer with 0.9% NaCl (w/v%). 
Ketoconazole (100 µM) was also included in these assays to rule out any CYP3A4 
binding. The inhibitor was added before the test compound and was allowed to incubate 
with the protein for 15 minutes. After seven hours of dialysis, the sample was aspirated 
from the chamber. The UV absorbance was recorded for both sides of the membrane, and 
the extent of protein binding was calculated as follows: %  𝑃𝑟𝑜𝑡𝑒𝑖𝑛  𝐵𝑖𝑛𝑑𝑖𝑛𝑔 = 100  × !!"#$%&'!!!"##$%!!"#$%&'   
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3.7 Development of Rat PBPK Models for Tacrine and Derivatives 
3.7.1 Software Used 
All PBPK models were created using the software PK-Sim® (version 5.5; Bayer 
Technology Services GmbH, Leverkusen Germany). This software generates models 
with a total 17 compartments representing organs and tissues, which are further divided 
into sub-compartments of red blood cells, plasma, interstitial space and cellular space. 
The compartments are connected via blood flows, with the system being closed via the 
lung (Figure 14). These models incorporate anatomical and physiological parameters for 
humans and several commonly used preclinical animals. For each organism, the software 
includes databases to describe how these parameters depend on the weight and/or height 
of the organism.  Using compound-specific physicochemical properties such as 
lipophilicity, plasma protein binding and molecular weight, PK-Sim® uses referenced 
and proprietary algorithms to provide estimates of absorption and distribution parameters 
such as organ-plasma partition coefficients and intestinal and cellular permeability. 
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Figure 14. Whole body PBPK model structure illustrating the 17 organ compartments 
and the venous and arterial blood flows that connect them. 
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3.7.2 Workflow for PBPK Model Development 
 Before developing models for the novel tacrine derivatives, a PBPK model for 
tacrine was first created (Figure 15). Several in vivo studies have been conducted with 
tacrine in rats, and the ability to compare simulated and observed concentration-time 
profiles offers the opportunity to optimize parameters and gain a more complete 
understanding of all processes influencing the absorption, distribution and elimination of 
tacrine. This type of comparison is not possible with the other compounds explored in 
this project as no in vivo studies have been conducted.  
 The initial tacrine model combines the rat-specific anatomy and physiology 
included in PK-Sim® with physicochemical and ADME data found in the literature. 
Concentration-time profiles were generated and compared to the in vivo rat data. In the 
case of considerable discrepancy between the simulated and observed data, uncertain 
model parameters such as permeability, clearance and transport activity were optimized 
until an acceptable goodness-of-fit was achieved. Particular emphasis was placed on 
achieving good fit for the curve representing unbound concentration in the brain 
interstitial space, as brain intracellular concentrations (where acetylcholinesterase is 
located) are used to determine dose.  
 Once the tacrine model was been optimized, the models for its derivatives could 
be developed. These models incorporated the same rat-specific parameters as the 
previous model, but used the data gathered from in silico and in vitro experiments for the 
compound-specific inputs such as lipophilicity, pKa, molecular weight, and intrinsic 
clearance. Although it was not possible to optimize derivative parameters by comparing 
to observed data, any optimized parameter from the tacrine model was similarly modified 
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from PK-Sim-estimated for the derivatives parameters. For example, PK-Sim® provides 
estimates of cellular and endothelial (in the case of the BBB) permeability based on the 
compound’s lipophilicity and effective molecular weight but the optimal value for 
permeability may differ from this estimate. When this situation arose, the ratio of the 
optimal to the estimated value for tacrine was used to scale the estimated values for the 
derivatives. When the models for the derivatives were fully parameterized, the dose was 
adjusted such that the desired brain concentrations were achieved. Target concentrations 
were defined as the concentration that inhibited 90% of AChE activity in vitro (AChE 
IC90).  
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Figure 15. Workflow for development of PBPK models for tacrine and derivatives. 
	   45 
 
3.7.3 Development of Rat PBPK Model for Tacrine 
 A rat PBPK model was created for tacrine based on a study conducted by Telting-
Diaz and Lunte,78 in which Sprague-Dawley rats were dosed with 1 mg/kg of tacrine 
intravenously and tacrine concentrations were measured both in blood and in brain 
interstitial space by microdialysis. The generic individual rat in PK-Sim has a body 
weight of 227.8 g, which was not representative of those used in the study (weight range 
350-450 g). The body weight was manually adjusted and all organism specific anatomy 
and physiology, such as organ volumes, blood flow rates were scaled accordingly by PK-
Sim. Physicochemical properties were obtained from the literature, including the blood-
to-plasma ratio (B:P), which was calculated using protein binding data from Telting-Diaz 
and Lunte, and the equation below:79 𝑓!,!  ×  𝐶! = 𝑓!,!  ×  𝐶! 
𝐵:𝑃 = 𝐶!𝐶! = 𝑓!,!𝑓!,! = 1− 0.5621− 0.733 = 1.64 
CYP1A2 is the only major enzyme in tacrine metabolism, accounting for 90% of 
tacrine clearance.28 In the preliminary model, clearance was attributed entirely to 
CYP1A2, with an arbitrary initial input of CLint = 1 L/min. Following simulation, the 
experimentally derived data for both blood and brain (interstitial unbound brain 
concentration) were superimposed onto the simulated concentration-time profiles. 
Because this model did not adequately reflect the observed data, parameters of clearance 
and distribution were optimized. The total blood clearance was slightly underestimated in 
the initial model, hepatic clearance via CYP1A2 being blood flow limited at 1 L/min. 
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Because CLint is not identifiable in a blood flow limited situation using optimization, 
hepatic CLint was reduced to the lowest value that did not result in a perceptible change 
in curve shape (0.7 L/min). Since clearance was underestimated, other clearance 
pathways were investigated. Evidence from the literature suggests that only a very small 
fraction of the tacrine dose is removed by urinary excretion in humans (0.5% of dose80). 
A similar estimate is not available for rats; as a result, glomerular filtration was the only 
renal clearance process incorporated into the model where renal clearance due to 
glomerular filtration was the fraction unbound in plasma multiplied by the glomerular 
filtration rate (fraction excreted unchanged in urine = 0.03). Once blood clearance was 
reasonable, brain concentrations were assessed for predictive accuracy with observed 
data. The simulation underestimated the extent of tacrine distribution into the brain 
(simulated Cmax: 0.115 µM; observed Cmax: 0.20 µM) and so an influx transporter 
representing organic cation transporter 2 (OCT2), a known tacrine transporter, 81 was 
incorporated into the blood-brain barrier to facilitate brain uptake. While the Km of the 
transporter is unknown, it is in the range of 0.02-4.3 µM, since researchers determined 
that this was the range of tacrine blood concentrations where brain uptake was 
saturable.81 For the purposes of modelling, a mid-range value of 1 µM was selected as 
the Km. Transport was parameterized with Michaelis-Menten type kinetics and Vmax was 
manually optimized using the observed brain data to 1.0 µmol/mL/min. Another 
discrepancy between the simulated and observed data was the rate of distribution into the 
brain, which was highly overestimated by the model; brain concentrations were predicted 
to be proportional to blood concentrations almost immediately whereas observed data 
showed that brain concentration did not come into equilibrium with blood until 0.6 h 
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post-administration. To improve curve shape at early time points, the permeability 
between plasma and brain interstitial space was decreased from 0.44 cm/s to 0.003 cm/s. 
Adjustment of these two parameters produced a brain concentration-time profile that 
reflected the experimental data reasonably. 
  
3.7.4 Development of Rat PBPK Models for Tacrine Derivatives  
 Upon fully parameterizing the tacrine model, analogous models were created for 
the tacrine derivatives using the same rat-specific anatomical and physiological 
parameters combined with predicted physicochemical and ADME data from in silico and 
in vitro experiments. ClogP was estimated using the ChemDraw Ultra software (version 
11.0, Cambridge Software Company) and pKa was determined in the Calculate 
Molecular Properties module of Discovery Studio. Fraction unbound was maintained at 
the same value as tacrine for all derivatives and CLint,s were determined through in vitro 
experimentation.  
 As mentioned previously, tacrine is known to be a substrate for the transporter 
OCT2 and the inclusion of this transport process was needed to achieve the observed 
concentrations in brain. The crystal structure of OCT2 has not yet been solved, and as a 
result, molecular docking studies similar to those conducted for P-gp were not possible. 
However, a number of studies using pharmacophore modelling have been conducted for 
OCT2 and a number of physicochemical properties influencing OCT2 substrate 
behaviour have been identified. By comparing the derivatives with tacrine for each of 
these properties, the likelihood that these compounds would also be OCT2 substrates was 
assessed. 
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Chapter 4.0 Results and Discussion 
 
4.1 Initial Compound Selection 
 Before beginning the in vitro experiments, 25 compounds were screened using 
existing target affinity data and calculated lipophilicity. Although several of the 
compounds displayed dual cholinesterase inhibition, an emphasis was placed on potency 
towards AChE. Under normal physiological conditions and in early stages of AD, AChE 
takes on the primary role in ACh hydrolysis and is present at a concentration four times 
greater than that of BuChE; it is not until late stages of AD the BuChE becomes the 
prominent catalyst for ACh degradation.82 The majority of compounds eliminated during 
this step (n = 7) belonged to Class A (containing no halogen on the tetrahydroacridine 
ring); in fact, all of the compounds from Class B (compounds chlorinated at the C-6 
position) were considered for further investigation. This suggests that the inclusion of a 
chloro group on the tetrahydroacridine ring at the C-6 and C-7 positions enhances 
affinity for AChE. However, the addition of a chloro group also increases a compound’s 
lipophilicity by 0.81 units, bringing many of the Class B and C compounds into an 
undesirable range of lipophilicity (Table 2) and potentially increasing the risk of toxicity. 
High lipophilicity resulted in the elimination of 9 compounds, leaving 9 compounds for 
further investigation. The majority of these compounds contain either a 3,4-
dimethoxybenzyl or a picolyl moiety at the C-9 position, suggesting that these groups not 
only convey target affinity, but are also hydrophilic enough to balance the effects of the 
chloro group on overall lipophilicity.  
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Table 2. Existing data used to select compounds for further investigation.  
 Physicochemistry 
Cholinesterase Inhibition 
(µM)a Aggregation Inhibition
b 
Compound MW ClogPc N + Od AChE BuChE Aβ1-40 Aβ1-42 
A1 288.39 5.52 2 6.96 0.41     
A2 318.42 5.44 3 5.81 0.09     
A3 318.42 5.44 3 3.34 0.08     
A5 348.42 5.18 4 2.23 0.02 59.8% 24.8% 
A6 362.42 5.83 4 4.57 0.08 41.1% 21.0% 
A7 289.38 4.02 3 6.65 0.07     
A8 289.38 4.02 3 3.99 0.22     
B1 323.85 6.33 2 1.67 3.99     
B2 353.87 6.25 3 2.98 2.38     
B3 353.87 6.25 3 0.61 5.22     
B4 353.87 6.25 3 0.72 9.10     
B5 383.89 5.99 4 0.85 1.40 64.8% 41.6% 
B6 397.87 6.64 4 0.63 1.86 65.7% 20.7% 
B7 324.38 4.83 3 0.10 1.61     
B8 324.38 4.83 3 0.19 12.73     
B9 324.38 4.83 3 0.03 1.37     
C1 323.85 6.33 2 2.59 12.11     
C2 353.87 6.25 3 5.10 4.25     
C3 353.87 6.25 3 1.89 8.25     
C4 353.87 6.25 3 3.37 11.65     
C5 383.89 5.99 4 1.26 9.27 77.3% 28.3% 
C6 397.87 6.64 4 3.17 7.27 35.9% 40.5% 
C7 324.83 4.83 3 7.06 6.78     
C8 324.83 4.83 3 7.69 >25     
C9 324.38 4.83 3 3.06 4.69     
Tacrine 198.27 3.27 2 0.215 0.05   
aIC50 values are the average of two to three separate experiments (n = 3) with mean 
deviation of less than 10%. bAggregation inhibition is reported as percent inhibition of 
the peak value (t = 6 hours) by 5 µM test compound and is the average of two separate 
experiments (n = 3). cClogP was determined using ChemDraw Ultra (version 11.0, 
Cambridge Software Company). dN + O is the number of nitrogen and oxygen atoms and 
gauges potential for hydrogen bonding. 
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4.2 Tacrine and its Derivatives as Substrates for CYP1A2 
4.2.1 Validation of CYP1A2 CDOCKER Protocol 
 To validate the docking protocol before its use on the novel derivatives, the co-
crystallized ligand (i.e. α-naphthoflavone) was docked into the specified binding sphere. 
The accuracy of the docking was assessed using the root mean square deviation between 
the heavy atoms of the co-crystallized ligand and those in the most favourable docked 
position.  
𝑟𝑜𝑜𝑡  𝑚𝑒𝑎𝑛  𝑠𝑞𝑢𝑎𝑟𝑒  𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =    1𝑁 𝛿!!!!!!  
In the above formula, δi is the distance between the ith corresponding heavy atoms and N 
is the total number of heavy atoms. The distances between corresponding atoms were 
between 0.225 and 0.455 Å and the root mean square deviation was 0.323 Å, well below 
the threshold required for docking to be considered successful (1.0-3.0 Å).83,84 
 
4.2.2 Evaluating Tacrine and its Derivatives as CYP1A2 Substrates 
The most favourable pose for tacrine docked within the CYP1A2 binding site 
shows a position similar to that of α-naphthoflavone, where the tetrahydroacridine ring 
system is inserted between the Gly316-Ala317 backbone and the Phe226 residue, 
allowing several π-π stacking and π-amide stacking interactions to occur (distance < 4 
Å). A hydrogen bond forms between a NH2 hydrogen and the C=O of Asp320 (distance 
= 2.3 Å), and several van der Waal’s interactions were seen with Ala317 and Leu497 
(distance < 5 Å). This pose also shows tacrine oriented with the cyclohexene ring 
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positioned closest to the heme group, which is most amenable to the formation of the 
major metabolite, 1-hydroxytacrine, as well as the minor products 2- and 4-
hydroxytacrine. However, the fifth and sixth most favourable positions show tacrine 
positioned with the benzyl ring nearest to the heme group, which would allow the 
formation of the 7-hydroxytacrine metabolite and subsequent production of toxic 
intermediates.  
In addition to the ability to observe a molecule’s position within a binding site, 
the Discovery Studio software also provides numerical scoring functions to quantify the 
stability of the ligand-enzyme complex and the affinity of the ligand for that enzyme. 
These parameters are called the CDOCKER energy (CDE) and CDOCKER interaction 
energy (CDIE), respectively. The CDIE reflects the affinity of a ligand for a protein, 
while the CDE incorporates both the interaction energy and the internal ligand strain 
energy to measure the stability of the ligand-protein complex. The most favourable pose 
for tacrine had CDE = -21.90 kcal/mol and CDIE = -35.16 kcal/mol. Tacrine’s affinity 
for CYP1A2 was also investigated in an in vitro setting, using a fluorescence-based 
recombinant CYP1A2 assay. From these experiments, tacrine was found to have a 
CYP1A2 IC50 of 1.483 ± 0.31 µM. This strong affinity for CYP1A2 correlates well with 
the energy parameters and the large number of close interactions with residues in the 
CYP1A2 active site.  
 In order to gain more insight into which pharmacophores are most desirable for 
increasing or decreasing CYP1A2 affinity, docking experiments were conducted for the 
full library of compounds and the following trends were observed. Firstly, the Phe226 
and Gly316-Ala317 backbone prove critical in CYP1A2 substrate binding as all 
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compounds interacted with these residues, regardless of their orientation within the 
binding site. These interactions consisted of stabilizing π-π stacking, π-amide stacking, 
and π-alkyl interactions with either the aromatic C-9 substituent or the tetrahydroacridine 
ring system. Additional π-alkyl interactions with Ala317 and Leu497 are also observed 
for all compounds, as well as π-π T-shaped interactions with the heme prosthetic ring. In 
addition to these interactions common to all compounds, each class of compound also 
undergoes distinctive contacts with surrounding residues. For example, the addition of a 
chlorine group at C-6 (i.e. Class B compounds) results in close van der Waal’s contact 
with Ser122 while the same substitution at C-7 (i.e. Class C compounds) promotes 
interaction with the Thr223 and Asp320 residues. Furthermore, there is a distinct trend 
when comparing the complex stability of corresponding compounds across the three 
classes (Figure 16). With the exception of the compounds with substituents 5 (3,4-
dimethoxybenzyl, Figure 6) and 6 (3,4-dimethoxyphenethyl, Figure 6), the CDE 
increases moving from Class A to Class C, differing by +9.11 kcal/mol on average. This 
suggests that the addition of a chlorine atom at the C-7 position has a significant impact 
on the internal ligand strain energy and results in a reduction in complex stability. A 
similar effect is observed for the Class B compounds, where the chlorine atom is at the 
C-6 position, but to a lesser degree (average increase in CDE: +5.09 kcal/mol).  
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Figure 16. Trends in CDOCKER Energy of CYP1A2 complexes for different C-9 
substituents across the three compound classes. 
 
The type of substituent at the C-9 position also impacts the way in which a 
compound binds to CYP1A2, which can be easily seen by dividing the compounds into 
two series: (i) substituted benzylamine series (R-groups 1-6) and (ii) picolylamine series 
(R-groups 7-9). From Figure 17, the addition of a substituted benzylamine group tends to 
increase CYP1A2 IC50, especially when this group becomes large in size (R-groups 5 
and 6). This effect is likely due to the narrow binding site of CYP1A2. As mentioned, the 
total active site volume for this enzyme is approximately 375 Å3 and typical CYP1A2 
substrates have molecular volumes below 200 Å3. The molecular volumes of the 
compounds containing a 3,4-dimethoxybenzylamine moiety approach 300 Å3. On the 
other hand, a picolylamine-substituted compound (which has a molecular volume of less 
than 215 Å3) shows CYP1A2 affinity equal to or higher than that of tacrine. The high 
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affinity of these picolylamine-containing compounds can be attributed to coordination 
between the picolyl nitrogen and the heme iron atoms. This effect is known as type II 
binding and is known to slow the catalytic action of various CYP450s by preventing the 
binding of oxygen to the heme, which can greatly enhance a drug’s metabolic stability.85 
These interactions have been studied in depth by Jones and coworkers, who investigated 
a number of groups containing sp2-hybridized nitrogen atoms and their ability to interact 
with heme iron using density functional theory calculations to quantify affinity for 
coordination. 86  This study also corroborated an in vitro observation that found 
replacement of the pyridine nitrogen in nicotine with a carbon atom reduced binding to 
the bacterial oxygenase CYP101A1 by more than 250-fold.87  
 
 
Figure 17. CYP1A2 IC50 values for selected compounds. Results are expressed as mean 
± SD (n = 3) for two independent experiments. *p < 0.05, unpaired Student’s t-test. 
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In order to most effectively prevent the formation of toxic species, we sought to 
eliminate any compounds that were not oriented with the C-9 substituent closest to the 
heme group for each of the ten most favourable conformations. This strict condition 
should not only prevent the direct production of the harmful 7-hydroxytacrine species, 
but also reduce the possibility of the formation and subsequent rearrangement of 1-, 2-, 
or 4-hydoxytacrine.  
 
Figure 18. Top: Tacrine derivatives oriented with the C-9 position close to the CYP1A2 
heme group. Bottom: Tacrine derivatives docked in an unfavourable orientation. Grey: 
tacrine; red: A8; blue: A5; orange: A6; maroon: C5. 
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Only compounds A3, A5, B5 and A8 were docked in this position consistently. A more 
detailed inhibition profile for tacrine and these four derivatives is shown in Figure 19.  
 
Figure 19. CYP1A2 inhibition profile of tacrine, A3, A5, A8 and B5 at increasing 
concentrations (0.01 – 20 µM). Results are expressed as % inhibition ± SD (n = 3) for 
two independent experiments. *p < 0.05, unpaired Student’s t-test. 
 
4.2.3 Correlation of In Vitro and In Silico CYP1A2 Data 
 The in vitro CYP1A2 assays provide a measure of the affinity of a compound for 
CYP1A2 by evaluating its ability to inhibit the metabolism of a known CYP1A2 
substrate. In silico docking experiments also estimate affinity by calculating the stability 
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of the ligand-enzyme complex. Although in vitro data is most commonly extrapolated to 
predict in vivo PK, the use of computational modelling techniques are gaining popularity 
as a more economic and less labour-intensive option. In light of this trend, the correlation 
between estimated compound-CYP1A2 complex stability and in vitro CYP1A2 IC50 was 
investigated. 
 
Figure 20. Correlation of in vitro CYP1A2 IC50 and CDE. Green: tacrine; purple: 
eliminated derivatives yellow: derivatives for further investigation; dashed horizontal 
lines: standard deviation from n = 3 in vitro experiments.  
 
A moderate correlation (R2 = 0.66963) was observed but it is important to consider that 
the compounds explored in this study were very structurally similar. Although the 
software may not be able to distinguish between different nitrogen positions in the 
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picolyl substituent, it is able to evaluate these compounds’ affinity for CYP1A2 relative 
to tacrine with accuracy.  
 
4.3 Tacrine and its Derivatives as Substrates for P-gp 
4.3.1 Determining Clinically Relevant P-glycoprotein Activity 
The inward facing conformation of the efflux transporter P-gp consists of 12 
helical transmembrane domains (TMDs) two nucleotide-binding domains (NBDs). P-gp 
has a large internal cavity with a volume of approximately 6000 Å3 and the ability to 
bind to two molecules simultaneously.88 The substrate-binding pocket of P-gp is known 
to be hydrophobic and lies at the interface of TMD6 and TMD12. 89  For these 
experiments, we used the crystal structure of mouse P-gp bound to the cyclic peptide 
QZ59-SSS (PDB file: 3G61), as a high-resolution structure of human P-gp has not been 
reported90. Rat P-gp shares 92% sequence identity with mouse P-gp, and shares ~100% 
identity within the P-gp substrate binding pocket.91 
The P-gp modelling studies were optimized by using the marketed anti-AD agent 
donepezil.92 Analysis of the most stable donepezil-P-gp complex shows that it binds deep 
in the internal cavity between TM7 and TM12 in a linear conformation. The 5,6-
dimethoxyindan-1-one moiety was in van der Waal’s contact with the Leu335, Ile336 
and Phe339 residues (distances < 5 Å). The benzylpiperidine substituent was oriented in 
a hydrophobic region comprised of Leu300, Leu720, Phe726, Phe766, Phe833, Val978 
and Ala981. The protonated piperidine NH underwent a hydrogen bonding interaction 
with the C=O of Gln721 (distance = 1.9 Å), and a π-alkyl interaction was observed 
between the benzylpiperidine aromatic ring and the isopropyl side chain of Leu300 
	   59 
(distance < 5 Å). A hydrophobic surface map of the donepezil binding region in P-gp 
indicates that the benyzlpiperidine ring is the major contributing factor in its ability to 
bind P-gp (EC50 = 34.85 ± 4.63 µM). In contrast, a similar modelling study of the 
antifungal agent ketoconazole shows that it binds in a hydrophobic region between TM6 
and TM12, and exhibits better binding affinity (CDIE = -39.27 kcal/mol) and stability 
(CDE = -20.03 kcal/mol) compared to donepezil (CDIE = -32.94 kcal/mol; CDE = -4.95 
kcal/mol). This can be attributed to its ability to interact with a greater number of 
hydrophobic regions in the substrate-binding pocket (EC50 = 9.74 ± 1.23 µM). The 
acetylpiperazine moiety was oriented toward a hydrophobic region whereas the 2,4-
dichlorophenyl ring was in van der Waal’s contact with Met68, Phe332, Leu335, Ile336, 
Phe339 and Tyr949 (distances < 5 Å). In addition, the 2,4-dichlorophenyl aromatic ring 
underwent an edge-to-face π-π interaction with Phe332 (distance < 5 Å). The C-2 
chlorine atom underwent an edge-in Cl-π interaction with Tyr949 aromatic ring (distance 
< 5.2 Å) whereas the C-4 chlorine underwent hydrophobic interactions with side chains 
of Met68 and Ile336 (distance < 5 Å). The imidazole aromatic ring formed a π-alkyl 
interaction with the CH3 group of Ala981 (distance < 5 Å). The construction of a 
hydrophobic surface map of the P-gp substrate-binding pocket clearly indicates the 
ability of ketoconazole to bind to multiple hydrophobic regions. It should also be noted 
that ketoconazole has a larger molecular volume (407.7 Å3) relative to donepezil (327.7 
Å3). These observations explain the superior P-gp inhibition exhibited by ketoconazole 
(EC50 = 9.74 ± 1.23 µM). 
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Figure 21.  P-gp inhibition profile of donepezil and ketoconazole at increasing 
concentrations (0.01-100 µM). Results are expressed as % inhibition ± SD (n = 3) for 
two independent experiments. 
 
Donepezil is a cholinesterase inhibitor that is widely prescribed to improve 
cognitive decline in AD patients. Literature data suggests that it undergoes liver 
metabolism primarily through the CYP3A4 enzyme,93,94 but donepezil’s status as a 
substrate for P-gp. has not been as well characterized; several recent publications 
disagree on this classification. A number of in vitro studies have reported that the efflux 
ratio for donepezil does not reach the minimum value needed to be considered a P-gp 
substrate. 95 , 96  Ishiwata and co-workers 97  demonstrated that donepezil’s brain 
permeability is compromised due to its interaction with P-gp in the endothelial cells. This 
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study also showed that the brain-to-blood ratio of radiolabelled donepezil increased 
significantly in the presence of a P-gp inhibitor. Furthermore, in a porcine in vitro blood-
brain barrier permeability model, donepezil was shown to be a relatively weak P-gp 
substrate at a substrate concentration of 3 µM.98 At unbound plasma concentrations 
resulting from single or multiple oral donepezil doses of 5 or 10 mg (total steady state 
concentration for 5 mg = 0.06 µM; unbound fraction = 0.04), it is unlikely that co-
administration of donepezil with P-gp inhibitors would result in a clinically significant 
enhancement of brain permeability.  
Other evidence to suggest that in vivo therapeutic concentrations, even in the 
gastrointestinal tract, are in the range of low P-gp inhibition that we determined in our 
study is the excellent oral bioavailability of donepezil (around 92%).99 Intestinal P-gp 
efflux of substrates tends to promote its metabolism by CYP3A4 due to the interplay 
between at the apical intestinal membrane.100 Some drugs, such as ketoconazole, are 
known to exhibit high affinity for CYP3A4 and P-gp, which can manifest in low oral 
bioavailability (absolute bioavailability in dogs is 50%; no human IV formulation).101 
The high oral bioavailability of donepezil confirms its low P-gp affinity. 
In conclusion, molecular modelling investigations of donepezil and P-gp indicate 
that interactions with the hydrophobic regions of the P-gp substrate-binding pocket 
contribute substantially to the stability of the complex. When compared to ketoconazole, 
donepezil undergoes fewer of these desirable interactions and displays a lower affinity 
for P-gp. The results of the in vitro P-gp assay corroborate this finding, indicating that 
donepezil is a weak substrate for P-gp at clinically relevant concentrations. Our study 
suggests that neither the co-administration of donepezil of P-gp inhibitors to enhance 
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brain permeability nor the concomitant use of other P-gp substrates is expected to result 
in clinically significant drug interactions. 
 
4.3.2 Evaluating Tacrine and its Derivatives as P-glycoprotein Substrates 
 Tacrine’s relationship with P-gp has been less controversial than that of 
donepezil. Several studies have determined in vitro that tacrine has an efflux ratio of 
approximately 1, indicating that its entry into the CNS is not modulated by P-gp.102,103 
Rather, it has been observed in rat brain that organic cation transporter (OCT) systems 
are likely involved in the transport of tacrine across the BBB.81 The most stable 
conformation of tacrine within the P-gp drug-binding site shows the tetrahydroacridine 
ring system in the same hydrophobic region as the benzylpiperidine and acetylpiperazine 
groups of donepezil and ketoconazole, respectively. As a result, tacrine undergoes some 
similar interactions with Val978 (hydrogen bond, 2.7 Å) and Ala981 (π-alkyl interaction, 
4.7 Å), found on TMD12. Additionally, π-amide stacking occurs between the Ala981-
Met982 peptide bond and the π-orbitals of tacrine (4.1 Å). However, tacrine is unable to 
form interactions with other TMDs as observed with donepezil (CDIE = -32.94 kcal/mol) 
and ketoconazole (CDIE = -39.27 kcal/mol) due to its smaller size and more isotropic 
shape and thus exhibits lower affinity for P-gp (CDIE = -20.57 kcal/mol). The stability 
of the tacrine-P-gp complex (CDE = -7.12 kcal/mol) is also considerably lower than that 
of ketoconazole (CDE = -20.03 kcal/mol) and similar to that of donepezil (CDE = -4.95 
kcal/mol). From these results, it is anticipated that tacrine would have a high EC50 for P-
gp and the in vitro P-gp assays confirm this (EC50: 348 ± 27.3 µM). 
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Figure 22. Comparison of tacrine (red), donepezil (blue) and ketoconazole (orange) 
positioning within the P-gp substrate binding site.  
 
 It was hypothesized that the tacrine derivatives may display enhanced P-gp 
binding due to their larger size (molecular volume range: 203.4 – 260.3 Å3) compared to 
tacrine (139.9 Å3). Generally, the tetrahydroacridine ring is situated in the same location 
as tacrine and also undergoes interactions with Val978 and Ala981, and the large C-9 
substituent is able interact with additional residues that were too distant from tacrine. 
This is reflected in the CDIEs of the tacrine derivatives (-25.28 to -31.99 kcal/mol; 
tacrine: -20.57 kcal/mol). Three out of four tacrine derivatives underwent close hydrogen 
bonding interactions with Gln721  (distance < 2.5 Å), which was also observed for 
donepezil and for the co-crystallized ligand QZ59-SSS104. This residue was reported to 
be the most common site for hydrogen bonding, despite the presence several other 
residues capable of hydrogen bonding in the drug-binding pocket.105Although they 
undergo a greater number of interactions, the complexes formed between P-gp and the 
tacrine derivatives are not very stable; the CDE parameter varied between -6.80 kcal/mol 
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and -8.97 kcal/mol. CDE appears to be more correlated with P-gp activity than CDIE, as 
ketoconazole and donepezil have quite different P-gp EC50’s and differ more in CDE 
(difference of 15.08 kcal/mol, compared to a difference of 6.33 kcal/mol for CDIE). 
Figure 23. Orientation of tacrine and derivatives within the P-gp substrate binding site. 
Red: tacrine; orange: A3; blue: A5; purple: A8; green: B5. 
 
 The in vitro assays support the hypothesis that additional substituents at the C-9 
position will increase the likelihood of P-gp binding. The tacrine derivatives displayed 
EC50 values that are significantly lower than tacrine (EC50 range: 52.4 ± 5.9 µM – 72.4 ± 
10.5 µM). Although these represent a significant change from tacrine, the derivatives still 
exhibit far less activity towards P-gp than donepezil. As a result, P-gp is not expected to 
have a noticeable impact on the PK profile of tacrine and its derivatives. 
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4.4 Evaluating Tacrine and its Derivatives as CYP3A4 Substrates 
 CYP3A4 is considered to be the most important enzyme in drug metabolism. It is 
estimated to have a role in the metabolism of 60% of all clinically used drugs and is 
frequently the cause of drug-drug interactions (DDIs).106 The prediction of DDIs in early 
phases of drug development has recently become a priority as several drugs have been 
removed from the US market due to DDI-related safety concerns.107 For these reasons, it 
is important to investigate the interactions of any candidate molecule with CYP3A4. For 
this study in particular, interaction with CYP3A4 must be explored for a second reason. 
Although CYP1A2 is the primary enzyme involved in the metabolism of tacrine, all 
members of the CYP450 family can catalyze oxidation reactions, so metabolism by any 
CYP isozyme may produce unwanted metabolites. Compounds A3, A5, A8 and B5 are 
oriented in a favourable position within the CYP1A2 active site but the binding site for 
CYP3A4 is considerably larger than that of CYP1A2 (1385 Å3 and 375 Å3, 
respectively31), and increases further upon ligand binding (1500-2000 Å3, Figure 24).108 
The additional volume may allow for different binding modes for these compounds and 
subsequent formation of toxic species. 
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Figure 24. Left: 3D structure of the CYP3A4 enzyme (PDB file name: 2V0M). Right: 
CYP3A4 active site. Blue: phenylalanine cluster; red: keto group; green: key binding 
residues; dark red: heme prosthetic group. 
 
 The CYP3A4 docking protocol was validated by docking the known ligand 
ketoconazole.92 Compound interactions with CYP3A4 were evaluated using the same 
techniques as the analogous studies with CYP1A2. As with the CYP1A2 study, any 
compounds oriented with the tetrahydroacridine ring closest to the heme group were 
eliminated. Of the four compounds docked, only one was eliminated based on the above 
criteria. A3 was unfavourably positioned in the two most stable complexes, and in four 
of the ten poses overall (Figure 25). 
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Figure 25. Orientation of tacrine derivatives within the CYP3A4 site. Dark red: heme 
prosthetic group; orange: A3; blue: A5; purple: A8; green: B5. 
 
Compounds A5 and B5 formed significantly more stable complexes with 
CYP3A4 as compared to CYP1A2 (CDE decreased by 10 and 21 kcal/mol, respectively).  
Since the CDIEs are approximately the same for both enzymes (approximately -45 
kcal/mol for both compounds, for both enzymes), the increased stability is likely due to 
the larger volume of the active site. Another common observation for both of the 3,4-
dimthoxybenzyl-substitued compounds is the formation of a close carbon hydrogen bond 
between a methyl hydrogen on the 4-methoxy group and the hydroxyl oxygen of residue 
Thr309 (distances < 2.3 Å), which encourages the molecule to dock with the C-9 group 
closest to the heme. The increased stability of the complex was more apparent for 
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compound A5 compared to B5. For A5, IC50 decreased by a factor of 10 (CYP1A2 IC50: 
33.0 ± 2.7 µM; CYP3A4 IC50: 3.7 ± 0.4 µM). Conversely, there was no significant 
difference between the B5’s IC50 for CYP1A2 and CYP3A4 (8.5 ± 1.5 µM and 13.8 ± 
1.1 µM, respectively).  
 Compound A8, which contains a 3-picolylamine substituent, displayed notably 
lower affinity for CYP3A4 than CYP1A2, despite the presence of three close interactions 
with residues Arg372 and Glu374 in the keto pocket (distances < 2.5 Å). This trend was 
also observed in the in vitro studies, as A8’s IC50 for CYP3A4 was 9.1 ± 1.1 µM 
compared to 1.0 ± 0.5 µM for CYP1A2. The overall orientation of A8 with respect to the 
heme group is similar to that observed in CYP1A2, and it is likely that the coordinate 
covalent bond between the picolyl nitrogen and the heme iron atoms described earlier 
also forms within the CYP3A4 binding pocket.  
 
4.5 Isolation and Characterization of Rat Liver Microsomes 
 Livers were obtained from three male Sprague-Dawley rats and weighed 7.45 g, 
12.95 g and 10.8 g for Rat #1, Rat #2 and Rat #3, respectively. Many different test 
systems exist for the investigation of metabolism kinetics. Hepatocytes offer the best 
recreation of the in vivo environment, as they contain both the CYP450s and phase II 
enzymes such as glutathione, sulfatases and S-transferases. However, their preparation is 
more complicated. Since the CYP450 enzymes are almost entirely responsible for the 
metabolism of tacrine, microsomes – the subcellular fraction containing the endoplasmic 
reticulum – are a suitable representation, and are simpler to isolate and more stable 
during storage.  
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 The protein content and cytochrome P450 reductase (CPR) activity of the 
microsomes were then quantified using the Bradford protein assay and a ferricyanide-
based assay, respectively. The protein content was 38.50, 36.22 and 32.41 mg of 
microsomal protein per gram of liver (MPPGL) for Rat #1, Rat #2 and Rat #3, 
respectively. These values are close to the 45 MPPGL often cited in the literature109 and 
correspond to a recovery rate of 72.0-85.6%. The reduction rate of ferricyanide was 
found to be 60.64, 27.11 and 25.35 mM per minute per milligram of microsomal protein.  
 
Table 3. Properties of isolated microsomes.  
Rat Liver Weight (g) 
MPPGL 
(mg/g) 
Recovery 
Rate 
Reduction Rate 
(mmol/L/min/mg) 
1 7.45 38.50 85.56% 60.64 
2 12.95 36.22 80.49% 27.11 
3 10.80 32.41 72.02% 25.35 
 
 
4.6 Measurement of In Vitro Intrinsic Clearance 
4.6.1 Substrate Depletion Studies 
Traditionally, enzyme kinetic parameters are evaluated by observing the rates of 
product formation at several different substrate concentrations. This method requires 
definitively identified metabolic pathways, but knowledge of such pathways and 
metabolites is often lacking in the early stages of drug development. In this scenario, the 
substrate depletion approach, in which the consumption of substrate is monitored over 
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time at multiple substrate concentrations, is a more practical approach.110 Furthermore, 
the substrate depletion method, proposed by Obach and Reed-Hagen in 2002,111 has been 
shown to be equivalent to the more traditional product formation approach.112  
 
 
Figure 26. Depletion of tacrine over time at various concentrations. 
 
Each of the curves in Figure 26 was fit to a single exponential to determine the depletion 
rate constant for each concentration. A plot of rate constant versus concentration was 
then produced and kdep([S]à0) and Km were extracted. 
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Figure 27. Plot of in vitro depletion rate constant versus tacrine concentration. 
 
The data in Figure 27 was fit to the following curve to obtain estimates of the depletion 
rate constant and the Michaelis constant: 
𝑘!"# = 𝑘!"#( ! →!) 1− [𝑆]𝑆 + 𝐾!  𝑘!"# = 0.015  𝑚𝑖𝑛!! 1− [𝑆]𝑆 + 49.3  𝜇𝑀  
The Km derived from this experiment (49.3 µM) was considerably greater than that 
reported by Obach and Reed-Hagen (1.4 µM). This is likely due to the fact that Obach 
and Reed-Hagen used recombinant human CYP1A2 microsomes at a concentration of 
0.92 mg/mL. Although the concentration used in this project was greater, these 
microsomes are not isozyme-specific and only contain the naturally occurring 
concentration of CYP1A2.112 Kinetic parameters for tacrine derivatives are shown in 
Table 5. 
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4.6.2 Microsomal Binding Assays  
Fraction unbound in microsomal protein was determined using microdialysis. The 
microdialysis set-up consists of two chambers separated by a membrane with pores such 
that the free ligand can cross the membrane but the receptor-bound ligand cannot. The 
ligand continues to diffuse across the membrane until the unbound concentrations on 
either side of the membrane are equal.  
 
Figure 28. Principle of microdialysis. Top: When protein binding does not occur, total 
ligand concentration on either side of the diffusion membrane are equal. Bottom: If 
protein binding occurs, unbound concentrations are equal but the total concentration is 
greater in the chamber containing the protein.  
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 Other methods for determining fraction unbound include equilibrium dialysis, 
ultrafiltration and ultracentrifugation. Equilibrium dialysis is typically considered to be 
the gold standard for protein binding studies. Both equilibrium dialysis and microdialysis 
use the same principle, but the smaller sample size used in microdialysis requires a 
shorter dialysis time, thereby reducing the likelihood of drug and/or protein degradation 
and microbial growth.113 The agreement between microdialysis and equilibrium dialysis 
has been studied extensively114,115; Le Quellec and coworkers found a correlation factor 
of r = 0.96 for samples from rabbit, rat, monkey and human.116  
 In the same way that drug bound to plasma proteins is unavailable to target 
tissues, drug that is bound to microsomal protein is assumed to be inaccessible to 
metabolizing enzymes. Overlooking nonspecific microsomal binding can significantly 
hinder predictions of in vivo clearance.117,118 Bases are particularly prone to high degrees 
of microsomal binding, and a strong correlation between lipophilicity and extent of 
binding has been observed at a protein concentration of 1 mg/mL119:  
𝑙𝑜𝑔 1− 𝑓!,!"#𝑓!,!"# = 0.53𝑙𝑜𝑔𝑃 − 1.42 
Given this trend, nonspecific binding to microsomal protein was expected to be a major 
factor in predicting clearance for tacrine and its derivatives. 
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Table 4. Fraction unbound in microsomal incubations 
Compound λmax fu,mic 
Tacrine 320 nm 0.012 
A5 340 nm 0.011 
A8 340 nm 0.010 
B5 270 nm 0.035 
 
4.6.3 Physiologically Based Scaling of In Vitro Intrinsic Clearance 
 In order to estimate the intrinsic clearance of the whole liver from in vitro kinetic 
parameters, a scaling factor (SF) must be applied. The SF must account for the amount of 
protein present in the incubation, the protein concentration in the liver, and the total size 
of the liver.  
𝐶𝐿!"# = 𝑘!"#({!]→!)× 1𝑓!,!"# × 𝑚𝐿  𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛𝑚𝑔  𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠×𝑚𝑔  𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠𝑔  𝑙𝑖𝑣𝑒𝑟 ×  𝑔  𝑙𝑖𝑣𝑒𝑟 
The first two terms in the scaling factor incorporates the fraction unbound in microsomes 
and the protein concentration for the incubation (2 mg/mL). The final two terms are 
known values from the literature. The average microsomal protein per gram of liver 
(MPPGL) for rat is 45 mg/g.120 A moderate correlation between rat liver weight and body 
weight has also been observed:121 %𝐿𝑊 = 5.92− 0.00286  𝐵𝑊 
where %LW is the liver weight as a percentage of body weight. From this relationship, a 
rat with a body weight of 400 g would have liver that weighs 4.776% of its total body 
weight, or 19.1 g. Plugging these three values into the equation above produces the 
following relationship: 
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𝐶𝐿!"# = 429.75𝑓!,!"# 𝑘!"#([!]→!) 
where CLint has units of mL/min.  
 
Table 5. Kinetic parameters from substrate depletion studies and scaled estimates of in 
vitro intrinsic clearance. 
Compound kdep([S[à0) Km fu,mic CLint,s 
Tacrine 0.015 min-1 49.3	  µM 0.012 537 mL/min 
A5 0.013 min-1 48.1 µM 0.011 508 mL/min 
A8 0.015 min-1 55.5 µM 0.010 645 mL/min 
B5 0.011 min-1 52.1 µM 0.035 135 mL/min 
 
It is important to note that the physiologically based approach for scaling in vitro CLint 
has been shown to systematically underpredict in vivo CLint, and this bias cannot be 
corrected without in vivo data.122 For tacrine, the optimized minimum CLint was 700 
mL/min. However, upon optimizing the PBPK model, it became apparent that hepatic 
clearance was blood flow limited and that direct scaling of the values in Table was not 
directly translatable even in the presence of observed data. Nevertheless, the relative 
values between tacrine and its derivatives could provide valuable information for 
parameterization, as discussed in the next section. 
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4.7 Development of PBPK Models for Tacrine and Derivatives 
4.7.1 Choice of Model Animal 
 PBPK models of tacrine and its derivatives were developed for rats for several 
reasons. First, rat physiology is better characterized than mouse physiology, and is also 
more human-like.123 A number of studies have examined the ability of the rat to reflect 
human responses to various stimuli, and the differences between the rat and human 
reactions are often insignificant.124,125 Rats are also much larger than mice, allowing for 
larger sample volumes, easier surgeries and higher resolution imaging in preclinical 
studies. Additionally, several rat models of Alzheimer’s disease have been developed in 
recent years using both transgenic and non-transgenic rats. These rats display 
amyloidosis, hyperphosphorylated tau and neuronal loss in the cerebral cortex and 
hippocampus.126,127 Because they are both more social and more intelligent than mice, 
the behavioural changes and cognitive impairment associated with Alzheimer’s disease 
can be observed more easily in rat models; this well-defined behaviour can be extremely 
useful in accurately assessing cognition.128  
 
4.7.2 Parameterization of Tacrine Model 
 The initial tacrine model was parameterized using data from several literature 
sources, including plasma protein binding data and dosing protocol from Telting-Diaz 
and Lunte81, physicochemical properties from Goh et al.129 and pKa from Perrin130 (Table 
4).  
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Table 6. Physicochemical input parameters for the rat IV tacrine model. 
Parameter Value Reference 
Molecular Weight 
(g/mol) 198.27 Goh et al., 2010 
ClogP 3.27 Goh et al., 2010 
pKa 9.95 Perrin, 1972 
B:P 1.64 Telting-Diaz and Lunte, 1993  
Fraction Unbound 0.438 Telting-Diaz and Lunte, 1993 
 
   
Originally, the model was parameterized with no transporter activity at the blood-
brain barrier. If brain concentrations were overpredicted, then the P-gp data that was 
collected in vitro would be integrated into the model. In silico and in vitro experiments, 
as well as previous studies found in the literature, suggested the P-gp would not be a 
major determinant in tacrine’s disposition. The results of the first simulation indicated 
that the model was in fact underpredicting brain concentration, and so tacrine transport 
by P-gp was deemed negligible. In order to achieve the brain concentrations observed in 
the Telting-Diaz study, an influx transporter into the brain was incorporated. The most 
common uptake transporters are the solute carrier (SLC) family of proteins. Like P-gp, 
the SLC family of proteins consist of 12 TMDs but little is known about how substrates 
interact with this family of proteins. There are more than 300 members in the SLC 
family, which are further divided in 52 sub-groups including transporters for urea, amino 
acids and acetyl-CoA.131 Since tacrine is protonated at physiological pH, the increased 
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uptake observed in the in vivo study is likely due to a member of the organic cation 
transporter (OCT) group. The OCT family contains at least five distinct members: OCT1, 
OCT2, OCT3, OCTN1 and OCTN2. Sung and coworkers determined which members of 
the OCT family are present in the BBB of rat brain samples and tacrine’s affinity for 
each one.84 It was determined that only OCT2 and OCTN2 are localized in the BBB of 
rats, and that tacrine has a much higher affinity for OCT2 as compared to OCTN2, with 
an estimated KM in the low micromolar range.80 
 
Table 7. Optimized parameters for the rat IV tacrine model.  
Parameter Initial Value Final Value 
CYP1A2 CLint (L/min) 1.0 0.7 
Brain Permeability (cm/min) 0.4447 0.003 
Kp,braina 3.4912 3.4912 
OCT2 Vmax (µmol/mL/min) 0 1.0 
P-gp Vmax (µmol/mL/min) 0 0 
aAccumulation due to passive transport as defined using Rodgers and Rowland 
algorithms for prediction of organ:plasma partition coefficients.132 
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Figure 29. Simulated (lines) and observed (dots) concentration-time data for tacrine 
following a 1 mg/kg IV bolus administration.   
 
4.7.3 Parameterization of Tacrine Derivative Models 
 Since brain permeability was overpredicted in the tacrine model, this parameter 
was also modified in the models for the tacrine derivatives. The new value for 
permeability was obtained by multiplying by the ratio of optimal to estimated brain 
permeability for tacrine.  
𝑝𝑒𝑟𝑚𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦  𝑠𝑐𝑎𝑙𝑖𝑛𝑔  𝑓𝑎𝑐𝑡𝑜𝑟 = 𝑜𝑝𝑡𝑖𝑚𝑎𝑙𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 = 0.003  𝑐𝑚/𝑚𝑖𝑛0.4447  𝑐𝑚/𝑚𝑖𝑛 = 0.00675 
Although tacrine is a known substrate for OCT2, it is unknown how the 
derivatives would interact with this protein. As mentioned, little is known about this 
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family of transporters, including their 3D structure. As a result, molecular docking 
experiments were not an option for predicting substrate behaviour. However, a 
pharmacophore modelling approach has been employed by a number of groups and 
several indicators of OCT2 substrate behaviour have been explored. These include 
molecular volume, polar surface area, logD7.4,133 aromaticity, ionization,134 logP and 
molecular shape.135 
 
Table 8. Properties determining OCT2 substrate behaviour and how these properties 
differ between tacrine and its derivatives 
Study Property Effect on Transporta Tacrine A5 A8 B5 
Hendrickx 
et al. 
(2013)127 
Molecular 
volume $ 139.9 Å
3 249.4  Å3 201.0 Å3 260.3  Å3 
Polar 
surface area $ 38.90 Å
2 43.4 Å2 37.8 Å2 43.4 Å2 
logD7.4 # 2.02 4.05 2.89 4.75 
Xu et al. 
(2013)128 
Aromaticity # ✔ ✔ ✔ ✔ 
Positive 
charge # 1+1 10 1+1 10 
Suhre et al. 
(2005)129 
logP # 3.27 5.18 4.02 5.99 
Length of 
molecule No effect n/a n/a n/a n/a 
. a An arrow pointing up (down) indicates a positive (negative) correlation between 
OCT2 transport and the corresponding property. 
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In many cases, the tacrine derivatives display properties that are equally or more 
favourable for OCT2 transport than tacrine. The most likely attribute to decrease 
transport by OCT2 is their size, which is significantly greater than tacrine (44-86% 
larger). However, the study by Suhre and coworkers examined a range of structurally 
diverse organic cations, many of which are similar to compounds A5, A8 and B5 in 
terms of size. For example, the crystal of violet dye, which has a molecular weight of 
407.98 g/mol, has IC50 values of 2.6 ± 1.2 µM in human OCT2 and 2.05 ± 0.2 µM in 
rabbit OCT2. For this reason, it was predicted that size would not impede the transport of 
tacrine derivatives by OCT2 and they were parameterized using the same values as 
tacrine. 
PBPK models were developed for each derivative using the same rat-specific 
inputs (e.g. organ volumes and blood flows) as were used for tacrine. The input 
parameters relating to each derivative are presented in Table 7. A final rat PBPK model 
following IV administration of 1 mg/kg was created for A5, A8 and B5. 
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Table 9. Summary of tacrine derivative-specific parameters for the rat IV PBPK models. 
 Value 
Parameter A5 A8 B5 Source 
Molecular Weight 
(g/mol) 348.42 289.38 382.88 Mass spectrometry 
Halogens present? None None 1 Cl Chemical structure 
ClogPa 5.18 4.02 5.99 ChemDraw 
pKaa 8.5 8.5 8.61 Discovery Studio 4.0 
CLint,s (L/min) 0.7  0.7 0.7 
Substrate depletion 
studies and tacrine 
model 
Glomerular 
Filtration Yes Yes Yes Tacrine model 
P-gp Vmax 
(µmol/mL/min)  0 0 0 
In vitro assays and in 
silico molecular 
docking  
OCT2 Vmax 
(µmol/mL/min) 1.0 1.0 1.0 
Pharmacophore 
modelling 
Brain Permeability 
(cm/min) 0.0082 0.0017 0.04226 
Scaled based on 
tacrine model 
 
 
4.7.4 Dosing Guidelines for Preclinical Studies 
 In order for a drug to be effective, it must be present in a sufficiently high 
concentration at the site of action. In the case of the tacrine derivatives, the site of action 
is the brain intracellular space and the desired concentration will depend on each 
compound’s ability to inhibit AChE activity by 90% (IC90). To assess the dose needed to 
reach these concentrations, a multiple dose protocol was simulated for each compound 
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consisting of a 1 mg/kg dose given every 6 hours for 600 hours, such that all compounds 
had reached steady state in the brain. The average unbound, intracellular brain steady 
state concentration (Css) was determined for the 1 mg/kg dose (Table 8). Because of the 
non-linear aspects of the OCT2 transporter with a Km value on par with blood 
concentrations, dose could not be scaled linearly from the 1 mg/kg simulation. As a 
result, the dose was manually adjusted until Css reached AChE IC90. 
 
Table 10. Necessary IV dose to reach AChE IC90 in the brain intracellular space 
(unbound). 
 Css for 1 mg/kg dose (µM) AChE IC90 
 (µM) 
Necessary Dose 
(mg/kg) Compound 
Brain 
intracellular 
space 
Blood 
Tacrine 0.1 0.4 1.75 17.5 
A5 0.5 0.2 13.26 80 
A8 2.5 0.2 31.01 28 
B5 0.1 0.1 9.05 180 
 
From the above table, it is clear that compound A8 is able to accumulate in the brain to a 
much greater extent than the other molecules, including tacrine. As shown in Table 7, A8 
has the lowest passive BBB permeability, but this permeability is bidirectional (i.e. A8 
will both enter and leave the brain at the slowest rate). The slow passive diffusion into 
the brain is overcome by OCT2 transport, allowing for a steady increase in concentration 
and a lower dose needed to reach IC90. 
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Chapter 5.0 Conclusions and Future Studies 
 
 This project serves as a template for the further investigation of tacrine-based 
compounds for the treatment of AD. In summary, a library of multifunctional tacrine 
derivatives was further analyzed to determine which candidates are most likely to be 
successful in later stages of drug development. Existing data was used to single out 
molecules with potent AChE inhibition and to eliminate compounds that are likely to 
display undesirable PK due to high lipophilicity. To reduce the risk of hepatotoxicity, 
compounds were investigated using in vitro and in silico methods to assess their binding 
interactions with both CYP1A2, the primary enzyme in tacrine metabolism, and 
CYP3A4, the most common enzyme for drug metabolism. From molecular docking 
studies, it is clear that the issue of hepatotoxicity cannot be solved for tacrine simply by 
adding a large substituent at the C-9 position; the type and size of the substituent will 
both influence the binding mode within the CYP active site and dictate the site of 
metabolism. For this reason, molecular docking studies are a crucial step in compound 
development. Molecules that were predicted to produce nontoxic metabolites were then 
assessed for substrate behaviour toward P-gp. In silico and in vitro studies agreed with 
the literature data suggesting that tacrine does not undergo transport by P-gp. The 
derivatives displayed somewhat enhanced binding properties towards P-gp as compared 
to tacrine, but showed less P-gp activity than donepezil. As a result, lack of brain 
permeability due to efflux by P-gp is not a concern for this group of compounds. 
Substrate depletion studies were conducted to evaluate metabolic stability and derive 
intrinsic clearances. The process of selecting compounds is illustrated in Figure 29. The 
in vitro and in silico data described above were then incorporated into a PBPK model to 
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predict the dose needed to reach each compound’s IC90 in the brain as a guide for future 
preclinical studies. 
 
Figure 30. Process of eliminating compounds to identify lead candidates for in vivo 
preclinical studies. 
 
As shown in Figure 29 only 3 compounds displayed all of the desired characteristics 
based on the in vitro and in silico experiments. These characteristics are summarized 
below in Table 9.  
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Table 11. Summary of characteristics for modeled compounds. 
  Compound 
   A5 A8 B5 
CYP1A2 
Favourable 
binding 
orientation? 
✔ ✔ ✔ 
CDOCKER 
Energy 
(kcal/mol) 
-9.844 -31.32 -0.305 
IC50 (µM) 33.0 ± 2.7 1.0 ± 0.5 8.5 ± 1.5 
P-gp 
CDOCKER 
Energy 
(kcal/mol) 
-6.799 -7.396 -8.866 
IC50 (µM)  63.5 ± 7.1 72.4 ± 10.5 52.4 ± 5.9 
CYP3A4 
Favourable 
binding 
orientation? 
✔ ✔ ✔ 
CDOCKER 
Energy 
(kcal/mol) 
-20.394 -19.806 -21.739 
IC50 (µM)  3.7 ± 0.4 9.1 ± 0.7 13.8± 1.1 
Additional 
Information 
Cell 
Viability         
(25 µM) 
93.8% 100.0% 81.8% 
Dose to 
Reach IC90 
(mg/kg) 
80 28 180 
 
Considering all of the areas investigated, compound A8 appears to be the most 
promising candidate for further studies. It is the least lipophilic of all compounds 
investigated (ClogP = 4.02) and, as a result, is less likely to produce unwanted side 
effects. Its toxicity has been investigated in vitro, and cell viability was 100% and 82.1% 
at concentrations of 25 and 50 µM, respectively. The coordinate covalent bond formed 
between the picolyl nitrogen and heme iron anchors the molecule in a favourable binding 
position for both CYP1A2 and CYP3A4, likely preventing the formation of toxic 
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metabolites. It also displays the most favourable PK profile, requiring the lowest dose to 
maintain therapeutic concentrations in the brain, despite being the least potent AChE 
inhibitor of the remaining candidates. For these reasons, A8 is the compound that most 
warrants further investigation in vivo. Prior to these in vivo studies, the ability of A8 to 
inhibit the aggregation Aβ protein should be investigated, as no experiments of this kind 
have been conducted for a picolyl-substituted compound.  
In addition to in vivo PK studies guided by the dosing recommendations above, 
the metabolic profiles of the tacrine derivatives can be further elucidated by conducting 
substrate depletion studies in the presence of inhibitors of specific CYP450 isozymes 
such as α-naphthoflavone for CYP1A2 and ketoconazole for CYP3A4. Further 
confirmation of metabolite structure is also possible through further analysis by LC-MS, 
for more certain validation that hydroxytacrine metabolites are not being formed in an 
appreciable amount.  
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